Phase I Clinical Trial, to Evaluate the Safety and Tolerability of the Ophthalmic Solution PRO-174 Versus Sophixín Ofteno®, Elaborated by Laboratorios Sophia on the Ocular Surface of Ophthalmological and Clinically Healthy Subjects
Phase: PHASE1
Conditions: Conjunctivitis, Conjunctivitis, Bacterial
Sponsor: Laboratorios Sophia S.A de C.V.

CONFIDENTIAL 
  
 
 
 
  
Creation date: August 2016 
Phase I clinical study, to evaluate the safety and 
tolerability of the ophthalmic solution PRO-174 
versus Sophixín Ofteno®, elaborated by Sophia 
Laboratories, S.A. of C.V. on the ocular surface of 
ophthalmologically and clinically healthy subjects 
Protocol code: SOPH174-0816/I 
Protocol version: 1.1 
Date of the version: 18/04/2017 
Registry: 173301410A0149/2017 
Sponsor: Laboratorios Sophia, S.A. de C.V.  
 

 
 
 
 
 
 
 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 1 of 63 
 
1. Summary 
Title of the study: 
Phase I clinical study, to evaluate the safety and tolerability of the ophthalmic solution PRO-174 
versus Sophixín Ofteno®, elaborated by Sophia Laboratories, S.A. of C.V. on the ocular surface of 
ophthalmologically and clinically healthy subjects. 
Protocol code: 
SOPH174-0816/I 
Creation date: 
22/08/2016 
Protocol version: 
1.1 
Date of the version: 
18/04/2017 
Therapeutic indication: 
Eye antibiotic 
Study period: 
3 to 4 months 
Development phase: I 
Goals: 
To evaluate the safety and tolerability of the formulation PRO-174 manufactured by Sophia 
Laboratories, S.A. of C.V. on the ocular surface of clinically healthy subjects. 
Hypothesis: 
The ophthalmic solution PRO-174 presents a safety and tolerability profile similar to the 
comparator in healthy subjects. 
Methodology: 
Phase I clinical trial, controlled, of parallel groups, double blind, randomized, exploratory. 
Number of patients: 
30 subjects, divided into 2 groups [15 subjects (30 eyes) exposed per group] 
Diagnosis and main inclusion criteria: 
- Signed informed consent. 
- Systemically and ophthalmologically healthy subjects 
- Age between 18 to 45 years. 
-Both genders. 
- Blood tests [complete blood count (BHc), three element blood chemistry (QS) and liver function 
tests (PFH)] within normal parameters specified by the reference laboratory with a lower and 
upper margin of 10%. 
- Visual capacity 20/30 or better, in both eyes.-  
-Intraocular pressure ≥11 and ≤ 21 mmHg. 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 2 of 63 
 
 
 
Test product, dose and route of administration, lot number: 
- 
PRO-174. Levofloxacin 0.5% ophthalmic solution. Prepared by Sophia Laboratories, S.A. 
of C.V, Zapopan, Jalisco, Mexico. 
- 
 Dosage: 1 drop every 2 hours during the waking period (8 daily applications), on day 1 
and 2; continuing with 1 drop every 4 hours during the waking period (4 daily 
applications) from day 3 to 7. Both eyes. 
- 
Route of administration: ophthalmic 
Duration of treatment: 7 days 
Reference product, dose and route of administration, lot: 
 - Sophixin Ofteno. Ciprofloxacin 0.3% ophthalmic solution. Prepared by Laboratories Sophia, S.A. 
of C.V., Zapopan, Jalisco, Mexico. 
- Dosage: 1 drop every 2 hours during the waking period (8 daily applications), on day 1 and 2;  
continuing with 1 drop every 4 hours during the waking period (4 daily applications) from day 3  
to 7. Both eyes. 
- Route of administration: ophthalmic 
Evaluation criteria: 
Primary security outcome variables:  
       -      Presence of adverse events. 
- 
Intraocular pressure. 
- 
Visual ability 
- 
Laboratory tests: BHc, QS and PFH. 
- 
Ocular surface staining with fluorescein and lissamine green using Oxford scale 
- 
Ophthalmological signs: conjunctival hyperemia, chemosis. 
Primary outcome variables of tolerability: 
      - Burning 
     - Foreign body sensation 
     - Itching 
     - Eye comfort index  
Primary outcome variables of tolerability: 
- 
Burning 
- 
Foreign body sensation 
- 
Itching 
- 
Eye comfort index 
Statistical methodology: 
The data will be expressed with measures of central tendency: mean and standard desviation for 
the quantitative variables. The qualitative variables will be presented in frequencies and 
percentages. The statistical analysis will be carried out through the Mann-Whitney U test for 
quantitative variables for the difference between the groups. The intra-group difference will be 
made with the Wilcoxon rank test. The difference between the qualitative variables will be 
analyzed by means of X2 (Chi2). An alpha ≤ 0.05 will be considered significant. 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 3 of 63 
 
2. Content 
1. SUMMARY 
1 
2. CONTENT 
3 
3. INDEX OF ABBREVIATIONS 
7 
4. ADMINISTRATIVE STRUCTURE OF THE STUDY 
9 
5. INTRODUCTION 
11 
5.1 THEORETICAL FRAMEWORK 
11 
5.2 DEFINITION OF THE PROBLEM AND FUNDAMENTAL REASON 
12 
5.3 BACKGROUND 
12 
5.3.1 LEVOFLOXACINO 
12 
5.3.1.1Pharmacodynamic properties 
13 
5.3.1.2 Pharmacokinetics in ophthalmic application 
14 
5.3.1.3Clinical efficacy 
14 
5.3.1.4 Security 
16 
5.4 JUSTIFICATION 
16 
5.5 OBJECTIVES AND HYPOTHESIS 
16 
5.5.1 GENERAL OBJECTIVE 
16 
5.5.2 SPECIFIC OBJECTIVES 
16 
5.5.3 HYPOTHESIS 
17 
5.6 STUDY DESIGN AND PLAN 
17 
5.6.1 DISCUSSION OF THE STUDY DESIGN 
18 
6. MATERIAL AND METHODS. PARTICIPANTS, INTERVENTIONS AND VARIABLES 
18 
6.1 STUDY CENTER 
18 
6.1.1 ORGANIZATION OF THE CENTER 
18 
6.1.2 DOCUMENTATION TO BE DELIVERED TO SPONSOR 
19 
6.1.3 CLOSURE OF THE CENTER 
19 
6.2 ELIGIBILITY CRITERIA 
19 
6.2.1 INCLUSION CRITERIA 
19 
6.2.2 EXCLUSION CRITERIA 
20 
6.2.2.1 General criterias 
20 
6.2.3 ELIMINATION SCHEDULES 
20 
6.2.4 IDENTIFICATION OF SUBJECT 
20 
6.3 INTERVENTION 
21 
6.3.1 ADMINISTERED TREATMENTS 
21 
6.3.1.1 Treatment under study 
21 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 4 of 63 
 
6.3.1.2 Reference treatment 
22 
6.3.2 STRATEGIES TO IMPROVE ADHERENCE AND PROCEDURE TO MONITOR ADHERENCE 
23 
6.3.2.1 Procedure to monitor adherence 
23 
6.3.2.2 Procedure to determine adherence 
23 
6.3.3 TREATMENTS AND COMMITTED INTERVENTIONS ALLOWED AND PROHIBITED DURING THE STUDY 
24 
6.3.4 MANAGEMENT OF TREATMENT 
24 
6.3.4.1 Delivery and reception 
24 
6.3.4.2 Storage 
24 
6.3.4.3 Return 
25 
6.3.5 OVERDOSAGE 
¡ERROR! MARCADOR NO DEFINIDO. 
6.4 DISARMING VARIABLES 
25 
6.4.1 SECURITY VARIABLES 
25 
6.4.1.1 Primary outcome variables 
25 
6.4.1.2 Variables of primary outcome of tolerability 
25 
6.4.1.3 Secondary outcome variables 
26 
6.4.2 EFFECTIVENESS VARIABLES 
26 
6.4.2.1 Primary outcome variables 
26 
6.4.2.2 Secondary outcome variables 
26 
6.4.3 METHODS AND SCALES TO BE USED FOR THE MEASUREMENT OF VARIABLES 
26 
6.4.3.1 Visual capacity 
29 
6.4.3.2 Eye comfort index 
29 
6.4.3.3 Eye surface integrity: 
29 
6.4.3.4 Presence of adverse events 
30 
6.4.3.5 Intraocular pressure 
30 
6.4.3.6 Posterior segment 
30 
6.4.3.7 Life signs 
30 
6.4.3.8 Ocular Symptomatology 
31 
6.4.3.9 Rupture time of the tear film 
31 
6.4.3.10 Pregnancy test 
31 
6.4.3.11 Laboratory tests 
31 
6.4.4 TIME OF MEASUREMENTS 
31 
6.4 CHRONOGRAM AND STUDY DIAGRAM 
¡ERROR! MARCADOR NO DEFINIDO. 
6.5.1 PROCEDURES TO BE CARRIED OUT BY VISIT 
34 
6.5.1.1  Scrutiny visit 
34 
6.5.1.2 Baseline visit 
35 
6.5.1.3 Visit 1 
36 
6.5.1.4 Final Visit 
36 
6.5.1.5 Security Call 
36 
6.5.2 STUDY DIAGRAM 
36 
6.6 SAMPLE SIZE 
37 
6.6.1 CALCULATION OF SAMPLE SIZE 
37 
6.7 RECRUITMENT 
38 
7. METHODS. ASSIGNMENT OF THE INTERVENTION 
38 
7.1 GENERATION OF THE ASSIGNMENT SEQUENCE 
38 
7.2 BLINDNESS MECHANISM 
38 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 5 of 63 
 
7.3  IMPLEMENTATION 
38 
7.4 BLINDING (MASKING) 
38 
7.4.1 BLINKING OPENING 
38 
8. METHODS. DATA COLLECTION, ADMINISTRATION AND ANALYSIS 
39 
8.1 METHODS OF DATA COLLECTION 
39 
8.1.1 STRATEGIES TO COMPLETE FOLLOW-UP 
39 
8.2 ADMINISTRATION OF DATA 
40 
8.3 STATISTICAL METHODOLOGY 
40 
8.3.1 ANALYSIS OF PRIMARY AND SECONDARY DISPLACEMENT VARIABLES 
40 
8.3.2 ADDITIONAL ANALYSIS 
41 
8.3.3 POPULATION ANALYSIS AND HANDLING OF MISLEADING DATA 
41 
9. METHODS. MONITORING 
41 
9.1 DATA MONITORING 
41 
9.2 PRELIMINARY ANALYSIS AND EARLY TERMINATION OF THE STUDY 
42 
9.3 ADVERSE EVENTS 
43 
9.3.1 RESPONSIBILITIES OF THE INVESTIGATOR 
43 
9.3.1.1 Record of adverse events in the Case Report Form 
43 
9.3.1.2 Follow-up of adverse events 
45 
9.3.1.3Procedures for a serious adverse event 
45 
9.3.1.4 Evaluation of causality 
46 
9.3.2 RESPONSIBILITIES OF THE SPONSOR 
48 
9.4 AUDIT 
48 
9.4.1 AUDIT PRIOR TO STUDY 
48 
9.4.2 AUDIT / INSPECTION DURING STUDY DRIVING 
48 
10. ETHICAL CONSIDERATIONS 
48 
10.1 APPROVAL OF THE COMMITTEES 
48 
10.2 AMENDMENTS TO PROTOCOL 
49 
10.3 CONSENT 
50 
10.3.1 GETTING 
50 
10.3.2 SPECIAL CONSIDERATIONS 
50 
10.3.3 MODIFICATION TO INFORMED CONSENT 
51 
10.4 CONFIDENTIALITY 
51 
10.5 DEVIATIONS 
51 
10.5.1 MANAGEMENT OF DEVIATIONS 
52 
10.6 DECLARATION OF INTEREST 
52 
10.7 ACCESS TO INFORMATION 
52 
10.8 AUXILIARY CARE AND AFTER THE FINALIZATION OF THE STUDY 
53 
10.9 BIOSECURITY ASPECTS 
53 
10.10  FINAL REPORT AND PUBLICATION OF RESULTS 
53 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 6 of 63 
 
10.10.1 FINAL REPORT  
53 
10.10.2 COMMUNICATION OF RESULTS 
53 
10.10.3 PUBLICATION OF RESULTS 
53 
11. BIBLIOGRAPHICAL REFERENCES 
54 
12. SIGNATURE PAGE 
59 
13. ANNEXES 
61 
13.1 EYE CONFORT INDEX 
61 
13.2 EFRON SCALE FOR CONJUNCTIVE HYPEREMIA 
63 
13.3 OXFORD SCALE 
63 
 
 
Index of tables, figures and illustrations 
 
Table 1. Administrative structure ...................................................................................................... 9 
Table 2. Antibacterial activity of levofloxacin against ocular isolates in Japan ............................. 13 
Table 3. Quali-quantitative formulation of PRO-174 22 ................................................................. 15 
Table 4. Quali-quantitative formulation of Sophixín Ofteno .......................................................... 22 
Table 5. Scales to be used ................................................................................................................ 23 
Table 6. Algorithm of Karch and Lasagna modified by Naranjo ..................................................... 26 
 
Figure 1 Minimum organization of the center................................................................................. 19 
Figure 2. Diagram of the study ......................................................................................................... 37 
Figure 3. Attention to the adverse event ........................................................................................ 45 
 
Ilustration 1. Structural formula of levofloxacin ............................................................................. 13 
 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 7 of 63 
 
3. Index of abbreviations 
 
ALT 
 
 
Alanino transferase 
AST  
 
 
Aspartate transferase 
BD  
 
 
Bilirrubin direct 
BI  
 
 
Bilirrubin indirect 
BHc  
 
 
Complete blood count 
BPC 
 
 
Good clinical practice 
BT  
 
 
Total Bilirubin 
CV 
 
 
Visual capacity 
CCI 
 
 
informed consent letter 
CEI 
 
 
Research Ethics Committee 
CI 
 
 
Informed Consent 
CRF 
 
 
Case Report Form (Case Report Form) 
EA /EAS 
 
Adverse event / serious adverse event 
FDA 
Food and Drug Administration (Food and Drug Administration) 
FC 
 
 
Heart rate 
FR 
Respiratory frequency 
ICH 
International Conference on Harmonization (for its acronym in English 
International Conference on Harmonization) 
ICO 
Eye comfort index 
IP 
 
 
Principal investigator of the clinical study 
PFH  
  
 
Liver function tests 
PIO 
 
 
intraocular pressure 
TAS  
 
 
Systemic blood pressure 
TF 
 
 
Fluorescein staining 
TVL  
Green lysine stain 
QS  
 
 
Blood chemistry 
 
 
 
 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 8 of 63 
 
 
 Page left intentionally blank

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 9 of 63 
 
4. Administrative structure of the study 
The administrative structure of the sponsoring party, corresponding to Sophia Laboratories, S.A. of 
C.V is shown in Table 1. Administrative structure 
Function 
Name/ Contact 
Affiliation ¥ 
Medical responsible 
for the study 
Dr. Leopoldo Martín Baiza Durán 
leopoldo.baiza@sophia.com.mx 
Medical Director and Regulatory Affairs 
Director of the 
study 
Dr. Aldo Arturo Oregón Miranda 
aldo.oregon@sophia.com.mx 
Clinical Operations Manager 
Scientific Comittee 
Dr. Oscar Olvera Montaño 
oscar.olvera@sophia.com.mx 
Ophthalmologist Investigator 
Scientific Comittee 
Dr. en C. Arieh Roldán Mercado Sesma 
arieh.mercado@sophia.com.mx 
Medical Editor 
Coordinator of 
regulatory 
procedures 
LN. Ana Isabel Alcaraz Ledón 
ana.alcaraz@sophia.com.mx 
Specialist in the beginning of clinical 
studies 
Monitoring 
coordinator 
QFB Virginia Manuela Villa Félix 
virgina.villa@sophia.com.mx 
Monitor coordinator 
Monitor 
QFB Jessica Lizette Mejía Gutiérrez 
jessica.mejia@sophia.com.mx 
Senior Monitor 
Monitor 
LP María Angela González Ávila 
maria.gonzalez@sophia.com.mx 
Junior Monitor 
Monitor 
QFB Lizeth de Jesús Pérez Lerma 
lizeth.perez@sophia.com.mx 
Junior Monitor 
Monitor 
LN Pilar Carolina Castro Mata 
pilar.castro@sophia.com.mx 
Junior Monitor 
Administrative 
Assistant 
LAET Maira Alejandra Ramírez Velazco 
alejandra.ramirez@sophia.com.mx 
Clinical Operations Assistant 
¥ Employees of Sophia Laboratories, S.A. of C.V Av. Paseo del Norte No.5255, Col. Guadalajara Technology Park, 
Carretera Guadalajara-Nogales Km13.5 C.P45010 Zapopan, Jalisco, Mexico Tel +52 (33) 3000 4200 
 
 
Table 1. Administrative structure 
 
 
 
 
 
 
 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 10 of 63 
 
 Page left intentionally blank

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 11 of 63 
 
5. Introduction 
5.1 Theoretical framework 
The human being is constantly exposed to a wide variety of microorganisms, including bacteria, 
viruses and fungi. In the majority of the occasions, these microorganisms do not produce infections, 
because the skin and the superficial membranes provide an effective barrier before the invasion of 
these. Nevertheless, some microorganisms can directly invade these barriers, and others, take the 
opportunity to enter the human body through injuries, whether they are surgical or traumatic. 
Normally, if microorganisms manage to penetrate external barriers, the immune system deals with 
them effectively. Notwithstanding, some of it have special properties that allow them to overcome 
the immune system; in some cases the person's immune system is not functioning optimally, 
allowing microorganisms, which in normal situations would not represent a greater threat, cause an 
infection. [1]  
Throughout history, different types of compounds have been used to help the immune system fight 
these microorganisms. Each of the main categories of microorganisms that produce infections 
(bacteria, viruses and fungi) has a characteristic structure and metabolism. The differences are so 
significant that compounds that are toxic to an organism in one category usually do not have activity 
against members of the other two categories. Therefore, the compounds against these 
microorganisms are classified as antibacterial, antiviral and antifungal. [2]  
Besides, a single compound has no activity against all species of microorganisms within a category. 
The species against which a drug demonstrates intrinsic activity is known as the spectrum of action. 
A narrow spectrum is when the drug only has action against a few species, while a broad spectrum, 
has activity against a variety of species. [1]  
Fluoroquinolones are drugs that inhibit the synthesis of bacterial DNA, which leads to cell death. Its 
primary targets are topoisomerase II and topoisomerase IV, which are involved in the maintenance 
of the superhelical structure of DNA during synthesis. Human cells do not contain these enzymes, 
so they are not affected by fluoroquinolones. [3]  
Traditionally, fluoroquinolones have been classified into generations; Nevertheless, this 
classification has not been standardized and lacks formality. Nevertheless, it finds clinical utility in 
classifying them based on their spectrum of action and indications. [1] [3] 
Currently there are formulations available in ophthalmic solutions, fluoroquinolones second 
(ciprofloxacin, norfloxacin, ofloxacin), third (levofloxacin) and fourth generation (gatifloxacin, 
besifloxacin, moxifloxacin). These drugs have a broad spectrum and effectiveness against gram-
positive and gram-negative bacteria. Due to the increase in the resistance index, especially of gram-
positive bacteria, the clinical usefulness and effectiveness of the second generation 
fluoroquinolones has decreased. [1] [3]  
Infectious conjunctivitis is a common condition; It is estimated that close to 1% of medical 
consultations in the first level of care are related to this, affecting about 6 million people a year in 
the United States of America. [2] [4] [5] 
 
 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 12 of 63 
 
 Although only about a third of patients diagnosed with conjunctivitis, in the first level, the diagnosis 
of bacterial conjunctivitis is confirmed, 80% receive antibiotic treatment. [6] The bacterial etiology 
is varied, and depends on geographical and age factors, but the most common includes species of: 
Staphylococcus, Streptococcus, Haemophilus, Pseudomonas, Corynebaterium and Moraxella. [2]  
Some cases of bacterial conjunctivitis can be self-limiting, although they find use in the use of topical 
antibiotics, since they accelerate recovery and avoid complications that can range from mild 
superficial corneal erosion to permanent damage to the cornea that results in visual disturbances. 
[2] [7] Bacterial conjunctivitis is responsible for an annual cost of approximately $ 377 to $ 875 
million in the United States of America. [8] 
 
 5.2 Definition of the problem and fundamental reason 
Bacterial conjunctivitis and other ocular surface infections are a common condition throughout the 
world. It has been estimated that infectious conjunctivitis is suspected in 3% of patients treated by 
a general practitioner, and of these, the final diagnosis is made in two thirds. [7] In the United States 
of America, the incidence of bacterial conjunctivitis is 135 cases per 10,000 inhabitants per year. [8]  
The bacterial conjunctivitis is due to infections by several bacteria, among which are: Haemophilus 
Influenzae, Streptococcus pneumoniae or Staphylococcus aureus. It is considered self-limiting, 
nevertheless, the proper use of antibiotics accelerates recovery, reduces recurrences and prevents 
complications such as orbital cellulitis, keratitis and panophthalmitis. [9] [7] 
Currently in Mexico and other countries of the American continent where Sophia Laboratories, S.A. 
of C.V has presence, the use of levofloxacin 0.5% ophthalmic solution is not approved. So PRO-174 
could be a safe and effective option in the treatment of bacterial conjunctivitis and other ocular 
surface infections. 
5.3 Background 
 The ophthalmic solution of levofloxacin 0.5% is an antibiotic formulation, marketed and approved 
under the name of Cravit® (Santen Pharmaceutical, Co., Ltd., Osaka, Japan), for use in bacterial 
conjunctivitis and ocular surface infections in Japan; in the United States of America and Europe it 
is approved for the treatment of bacterial conjunctivitis under the names of Quixin® and Oftaquix®, 
respectively. The active ingredient is a synthetic antimicrobial agent of the fluoroquinolone family. 
[10] [11]  
Fluoroquinolones exert their antimicrobial activity by inhibiting topoisomerases II and IV, enzymes 
involved in the synthesis of bacterial DNA. Fluoroquinolones have been widely used in the treatment 
of bacterial infections due to their potent activity and broad spectrum of action against gram-
positive and gram-negative bacteria. In addition, its use in ophthalmic formulations is common, due 
to its known safety and efficacy profile in the treatment of ocular surface infections. [12]5.3.1 
Levofloxacin 
Levofloxacin is the L-enantiomer of ofloxacin, it has twice as much antimicrobial activity as this one; 
in neutral pH it has greater solubility in water than this, which allows the preparation of formulations 
with high concentrations. 
Chemical Name: (-) - (S) -9-Fluoro-2,3-dihydro-3-methyl-10- (4-methyl-1-piperazinyl) -7-oxo-7H-
pyrido [1,2,3 -of] -1,4 benzoxazin-6-carboxylic acid hemihydrate. 
Chemical formulaC18H20FN3O4 ● ½ H2O 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 13 of 63 
 
Molecular weight: 370.38 
Illustration 1. Structural formula of levofloxacin 
 
5.3.1.1 Pharmacodynamic properties 
Levofloxacin acts, like the rest of the drugs of the fluoroquinolone family, by inhibiting the 
topoisomerase II (DNA gyrase) and topoisomerase IV enzymes, essential for the synthesis of 
bacterial DNA. Topoisomerase II is involved in the supercoiling of DNA, and in the replication and 
transcription of bacterial DNA; topoisomerase IV helps separate the DNA formed from the one used 
as a template for replication. [13] 
 5.3.1.1.1 Antibacterial activity 
Levofloxacin has demonstrated activity, in vitro, against a wide range of gram positive and negative 
eye isolates. Demonstrated activity against methicillin-susceptible S. aureus, methicillin-susceptible 
coagulase-negative staphylococci, α-hemolytic group streptococci, S. pneumoniae (including 
susceptible, intermediate and penicillin-resistant strains), Enterococcus spp., Moraxella catarrhalis, 
H. influenzae, H aegyptius, Enterobacter spp., Proteus spp., Serratia spp., Klebsiella spp., 
Acinetobacter spp., Pseudomonas spp. and P acnes. See Table 2 
Table 2. Levofloxacin antibacterial activity against eye isolates in Japan 
Species (number of isolated)a 
MIC90 (µg/mL) 
LVX 
MXF 
GAT 
TFLX 
OFX 
NOR 
LOM 
Gram-positive bacteria 
 
 
 
 
 
 
 
S. aureus (56) 
3.13 
0.78 
1.56 
0.78 
 
 
 
     MSSA (299) 
0.25-05 
0.12 
0.25 
0.12 
0.5-1 
2-4 
2 
     MRSA (223) 
64-128 
8 
16 
>16 
>128 
>128 
>128 
MS CNS (100) 
0.5-2 
 
 
 
1-4 
4-8 
4-32 
MR CNS (100) 
4 
 
 
 
8 
32 
64 
S. epidermidis (447) 
3.13-8 
0.78-2 
1.56-2 
3.13-16 
 
 
 
S. α-hemolítico (43) 
1.56 
0.2 
0.39 
0.39 
 
 
 
S. pneumoniae (30) 
2 
0.25 
0.5 
0.25 
 
 
 
     S. pneumoniae (PS) (100) 
1 
 
 
 
2 
8 
8 
     S. pneumoniae (PI) (50) 
1 
 
 
 
2 
8 
8 
     S. pneumoniae (PR) (30) 
1 
 
 
 
2 
4-8 
8 
Enterococcus spp. (30) 
2 
 
 
 
4 
8 
8 
Enterococcus faecalis (32) 
1.56-2 
0.2-0.5 
0.39-1 
0.2-0.5 
 
 
 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 14 of 63 
 
Corynebacterium spp. (366) 
>128 
128 
64 
>16 
>128 
64 
128 
Corynebacterium 
macginleyi 
(136) 
>128 
64 
32 
>16 
 
 
 
Gram-negative bacteria 
 
 
 
 
 
 
 
Moraxella catarrhalis (60) 
≤0.06 
 
 
 
0.12 
0.25 
0.25 
H. influenzae  (133) 
≤0.06 
0.06 
0.03 
0.03 
≤0.06 
≤0.06 
0.12 
H. aegyptius (10) 
≤0.06 
 
 
 
≤0.06 
≤0.06 
≤0.06 
Enterobacter spp. (20) 
0.25 
 
 
 
0.5 
0.25 
1 
Proteus spp. (20) 
2 
 
 
 
4 
8 
8 
Serratia spp (71) 
0.25 
0.5 
0.5 
0.25 
0.5 
0.25-0.5 
0.5 
Klebsiella spp. (20) 
0.12 
 
 
 
0.25 
0.25 
0.5 
Acinetobacter spp. (30) 
0.25 
 
 
 
0.5 
8 
1 
Pseudomonas spp. (39) 
0.78-1 
1.56 
0.78 
0.2 
2 
4 
4 
P. aeruginosa (100) 
2-8 
 
 
 
4-16 
2-8 
4-16 
Gram-positive anaerobes 
 
 
 
 
 
 
 
Propionibacterium acnes (738) 
0.5-1 
0.25 
0.25 
1 
1-2 
8 
4-8 
a All isolates were tested against LVX. In two studies they were tested against OFX, NOR and LOM, and in two studies 
they were tested against MXF, GAT and TFLX 
GAT = gatifloxacin; LOM = lomefloxacin; MR CNS = coagulase negative staphylococcus resistant to methicillin; MRSA = 
S. aureus resistant to methicillin; MS CNS = coagulase-negative staphylococcus susceptible to methicillin; MSSA = S. 
aureus susceptible to methicillin; MXF = moxifloxacin; NOR = norfloxacin; OFX = ofloxacin; PI = intermediate 
susceptibility to penicillin; PR = resistant to penicillin; PS = susceptible to penicillin; TFLX = tosufloxacin 
Adapted from Keating GM, et al. [14] 
 
Levofloxacin has also shown bactericidal activity dependent on concentration and post-antibiotic 
effect of 2 -4.5 hours, depending on the pathogen. [15]  
 
5.3.1.2 Pharmacokinetics in ophthalmic application 
 
Route of administration: Ophthalmic. 
 
Release: immediate. 
Distribution: after instillation, in the bottom of a sac, of a drop of the ophthalmic solution of 
levofloxacin 0.5%, in healthy subjects, a Cmax of 221.06 μg / mL was obtained in tears in 15 minutes, 
detecting up to 1.37 μg / mL, 24 hours after instillation. [16] The concentrations, after the 
application of a drop of levofloxacin 0.5%, in conjunctiva, cornea and aqueous humor are 2.34 
(20min), 0.37 μg / mL (31 min) and 18.26 μg / mL (36 min) respectively. [17] [18] In one study, in 11 
subjects who underwent vitrectomy, the concentration in vitreous and aqueous humor was 
measured, after the application of 2 drops three times a day, the day before surgery, and every 20 
minutes in the 2 hours before surgery; the concentrations were 0.77 μg / mL and 0.02 μg / mL, for 
aqueous and vitreous humor respectively. [19] Plasma concentrations of levofloxacin were 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 15 of 63 
 
evaluated in 15 healthy subjects, who applied the ophthalmic solution of levofloxacin 0.5% for 15 
days; the highest measured mean concentration was 2.25 ng / mL, on day 4. [10]  
5.3.1.3 Clinical efficacy 
In Keating's review article, on the use of levofloxacin in the treatment of eye infections, the efficacy 
that has been demonstrated in various clinical studies in Japan, the United States of America and 
Poland is summarized. These were multicentre, masked, randomized studies. 
Table 3. Clinical efficacy of levofloxacin in the treatment of bacterial conjunctivitis. 
Author 
Treatment 
 Evaluation 
Point 
Response rates (% of patients) [number of 
evaluable patients] 
Clinical 
efficacy 
Microbial 
eradication 
Clinical cure 
Hwang et al [20] 
LVX 0.5%b 
Final visit 
 
92***[59] 
78*[59] 
 
PLb 
Final visit 
 
53 [55] 
61[56] 
 
LVX 0.5%b 
Final point 
 
90*** [60] 
77*[60] 
 
PLb 
Final point 
 
53 [57] 
60[57] 
Kitano et al [21] 
LVX 0.5%c 
 
93d [112] 
79 [112] 
 
 
TFLX 0.3%c 
 
94d,e[109] 
80 [110] 
 
Schwab et al [22] 
LVX 0.5%b 
Final visit 
 
89*d [103] 
 
 
OFX 0.3%b 
Final visit 
 
80d [92] 
 
 
LVX 0.5%b 
Final point 
 
90*d [109] 
76d 
 
OFX 0.3%b 
Final point 
 
81d [99] 
76d 
Shimomura et al [23] 
LVX 0.5%c 
 
98d[125] 
85f 
 
 
MXF 0.5%c 
 
94d,e[139] 
95**f 
 
Szaflik et al [24] 
LVX 0.5% tidg 
Final visit 
 
93 [40] 
85d [40] 
 
LVX 0.5% q2h→q4hb 
Final visit 
 
96 [37] 
92d [37] 
a 
a The final visit was on days 6-10 [20] [22] or on day 7 [24]. The end point was defined as the last observation 
carried out (last observation carried forward). 
b 
b One to two drops every 2 hours, in the waking period, on days 1 and 2. Followed every 4 hours, in the 
waking period, on days 3-5. 
c 
c One drop three times a day for 14 days. 
d 
d Primary endpoint. 
e 
e MXF [23] and TFLX [21] were not inferior to LVX at the lower limit of 95% of the confidence interval (CI) 
since the intergroup difference exceeded -10%: 95% CI -8.1, 1.4 [23] and 95% CI -5.9.7.3 [21]. 
f 
f Microbial eradication index accumulated on day 15. 
g 
g One to two drops three times a day during the wake period for 5 days.MXF = moxifloxacino; OFX= 
ofloxacino; PL= placebo; qxh= every x hours; TFLX= tosufloxacino; *p<0.05, ** p<0.01, ***p<0.001 against 
comparator. 
Adapted from Keating GM, et al. [14] 
 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 16 of 63 
 
5.3.1.4 security 
The safety of levofloxacin was evaluated in the previously mentioned clinical studies, and in a phase 
IV study. The population included in the safety analysis of these studies was 244 [20], 413 [22], 331 
[23], 340 [21] and 6,686 [25]  
In general, 0.5% levofloxacin ophthalmic solution has been well tolerated, most of the adverse 
events related to treatment reported in the studies were of a mild to moderate intensity. In the 
phase IV study, 42 patients (0.63%) were reported with an adverse reaction, none of which was 
classified as serious. The reactions that were reported most frequently were: blepharitis, eye 
irritation, punctate keratitis, keratitis and pruritus; there was only one non-ocular reaction report 
(contact dermatitis, urticaria and oral numbness). 
In the controlled studies, there was no statistical difference between the events reported in the 
levofloxacin group and control. 
The most frequent adverse reactions in the entire study population were: transient decrease in 
visual acuity, fever, foreign body sensation, headache, transient burning, pain or ocular discomfort, 
pharyngitis and photophobia. These occurred in approximately 1-3% of patients. Other reported 
reactions, which occurred in less than 1% of patients, included allergic reactions, eyelid edema, dry 
eyes and pruritus. [10]  
5.4 Justification 
Although eye infections can be considered minor infections, they can threaten eyesight. Topical 
antibiotics are widely prescribed for the treatment of eye infections or as peri-surgical prophylaxis. 
An antibiotic drug must have a selective toxicity; it must be more toxic to the microorganism than 
to the patient. Ideally an antibiotic should kill the microorganism and cause minimal or no adverse 
effect on the user. 
Levofloxacin, active ingredient of PRO-174, is a third-generation fluoroquinolone that has been 
formulated as an ophthalmic solution and approved in countries with high pharmacological 
surveillance, for use in the treatment of eye infections caused by susceptible strains. In Japan it is 
approved for the treatment of bacterial conjunctivitis, other ocular surface infections and in surgical 
prophylaxis. In the United States of America, it has been approved for the treatment of bacterial 
conjunctivitis since August 2000. Currently, Mexico does not have approval for its use. 
Within the development of PRO-174, by Sophia Laboratories, S.A. of C.V, it is required the 
elaboration of clinical studies that evaluate the safety and tolerability of its ophthalmic use, which 
are the foundation of future clinical studies that prove effectiveness. Although there is sufficient 
bibliographic reference of the active principle of PRO-174, the current commitment of Sophia 
Laboratories, S.A. of C.V is to generate proprietary information for their products that serves for the 
relevant regulatory procedures, and as a scientific basis for their commercialization. 
5.5 Objectives and hypotheses 
5.5.1 General purpose 
To evaluate the safety and tolerability of the ophthalmic solution PRO-174 manufactured by Sophia 
Laboratories, S.A. of C.V on the ocular surface. 
5.5.2 Specific objectives 
 
 
Describe the safety of the PRO-174 ophthalmic solution through the presentation of adverse 
events. 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 17 of 63 
 
 
Describe the safety of the PRO-174 ophthalmic solution through changes in intraocular 
pressure. 
 
Describe the safety of the ophthalmic solution PRO-174 by means of changes in visual 
capacity. 
 
Describe the safety of the PRO-174 ophthalmic solution through changes in laboratory tests. 
 
Describe the safety of the ophthalmic solution PRO-174 through changes in ocular surface 
stains. 
 
Describe the safety of the ophthalmic solution PRO-174 through changes in 
ophthalmological signs (conjunctival hyperemia and chemosis). 
 
Describe the safety of the ophthalmic solution PRO-174 by means of changes in the time of 
tear rupture. 
 
Describe the safety of the PRO-174 ophthalmic solution through changes in vital signs. 
 
Describe the safety of the ophthalmic solution PRO-174 by means of changes in the 
posterior segment. 
 
Describe the tolerability of the ophthalmic solution PRO-174 through the presence of ocular 
symptoms (burning, foreign body sensation and pruritus). 
 
Describe the tolerability of the ophthalmic solution PRO-174 through changes in the ocular 
comfort index. 
 
Describe the safety of the Sophixín Ofteno® ophthalmic solution through the presentation 
of adverse events. 
 
Describe the safety of the Sophixin Ofteno® ophthalmic solution through changes in 
intraocular pressure. 
 
Describe the safety of the Sophixín Ofteno® ophthalmic solution through changes in visual 
ability. 
 
Describe the safety of the Sophixin Ofteno® ophthalmic solution through changes in 
laboratory tests. 
 
Describe the safety of the Sophixin Ofteno® ophthalmic solution through changes in ocular 
surface stains. 
 
Describe the safety of the Sophixín Ofteno® ophthalmic solution through changes in 
ophthalmological signs (conjunctival hyperemia and chemosis). 
 
Describe the safety of the Sophixin Ofteno® ophthalmic solution by means of changes in the 
tear rupture time. 
 
Describe the safety of the Sophixín Ofteno® ophthalmic solution through changes in vital 
signs. 
 
Describe the safety of the Sophixín Ofteno® ophthalmic solution through changes in the 
posterior segment. 
 
Describe the tolerability of the ophthalmic solution Sophixín Ofteno® by means of the 
presence of ocular symptoms (burning, sensation of foreign body and pruritus) 
 
Describe the tolerability of the ophthalmic solution Sophixín Ofteno® by means of changes 
in the ocular comfort index. 
5.5.3 Hypothesis 
Ha The ophthalmic solution PRO-174 presents a safety and tolerability profile similar to the 
comparator in healthy subjects. 
 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 18 of 63 
 
Ho The ophthalmic solution PRO-174 presents a safety and tolerability profile different from the 
comparator in healthy subjects.  
 
5.6 Design and plan of the study 
Phase I clinical trial, controlled, of parallel groups, double blind with randomization, exploratory. 
5.6.1 Discussion of the study design 
The design of the study (clinical trial) is considered the highest quality standard in the data when it 
is sought to explore the effect of an intervention. The phase of pharmacological development (phase 
I) corresponds to the objective of the study which is to assess safety and tolerability, so that the 
intervention time is short and the sample size required is less than that of a clinical efficacy trial. The 
presence of parallel groups allows the comparison between the intervention groups on the outcome 
variables. Blinding and randomisation allow to reduce biases that are incurred with other designs, 
eg. selection bias, evaluation bias, among others.  
 
6. Material and methods. Participants, interventions and variables 
6.1 Study Center 
The present study will be performed in ophthalmology offices duly equipped and registered for their 
proper functioning. According to the needs of the sponsor, these may be private or public, be 
attached to a hospital or clinic or be independent. 
6.1.1 Organization of the center 
Each study center will have a principal investigator (PI). The PI is the ophthalmology specialist in the 
clinical study. 
The PI is responsible for forming a multidisciplinary research team to carry out the clinical study 
according to protocol, under its scientific guidance. It is the prerogative of the IP the design of the 
organization of its center and the selection of the personnel that will perform the functions. 
Notwithstanding, the minimum organization of the research team requested by the sponsor 
requires the figure of sub-researcher, study coordinator and pharmacist. (See Figure 1 Minimum 
organization of the center) 
Any person to whom the PI designates, under his / her responsibility, a part of the follow-up of the 
study (co-investigator, under-researcher, nurse, etc.) or a specific function of participation in the 
study (pharmacist, administrative assistant, study coordinator, etc.) should appear in the format 
of"Delegation of Responsibilities". 
 
 
 
 
 
 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 19 of 63 
 
 
 
 
 
 
 
 
 
 
Figure 1 Minimum organization of the center 
The "Delegation of Responsibilities" and the "Organizational Chart of the Center" must be delivered 
to the sponsor before the start of the study and updated if the members or their responsibilities are 
changed. 
6.1.2 Documentation to be delivered to the sponsor 
The PI must deliver to the sponsor, before the start of the study: 
- Curriculum vitae updated, in Spanish, dated and signed (maximum 10 pages), of the IP and the 
staff that integrates its organizational chart of the center. 
- Copy of IP academic certifications (degree certificate and specialty diploma in ophthalmology, 
federal professional certificates) 
- Copy of academic certifications of the maximum degree obtained, from each one of the members 
of your research team, that cover their capacity to perform the delegated functions. 
- Copy of operating notice or similar issued by corresponding regulatory entity (When applicable) 
- Certificate of good clinical practice in force. If the issuing institution does not specify the validity 
period in the certificate, the date of issue of the certificate must not exceed one year 
6.1.3 Closure of the center 
The closing of the center will be carried out once the last visit of the last included subject previously 
agreed between the sponsor and the IP has been made. The closing process will be according to the 
internal operating procedures of the sponsor. 
It is the sponsor's prerogative to prematurely close a study center, it must inform the IP the reasons 
for the closure. 
6.2 Eligibility criteria 
6.2.1 Inclusion criteria 
 
- 
Signed informed consent. 
- 
Systemically and ophthalmologically healthy subjects evaluated during the clinical history. 
- 
Age between 18 to 45 years. 
- 
Both genders. 
- 
Blood tests [complete blood count (BHc), three element blood chemistry (QS) and liver 
function tests (PFH)] within normal parameters specified by the reference laboratory with 
a lower and upper margin of 10%. 
Principal 
investigator
Subinvestigador
Pharmacist
Study 
coordinator

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 20 of 63 
 
- 
Vital signs within normal parameters. (Vital signs at rest: blood pressure ≤ 139/89 mmHg, 
heart rate 60 -100 beats per minute and respiratory rate of 12-24 breaths per minute).  
- 
- Visual capacity 20/30 or better, in both eyes. 
- 
- Intraocular pressure ≥11 and ≤ 21 mmHg. 
6.2.2 Exclusion criteria 
6.2.2.1 General criteria 
 
Subjects with a history of hypersensitivity to any of the components of the research 
products. 
 
Subject users of topical ophthalmic medications of any pharmacological group. 
 
Subject users of medication by any other route of administration. 
 
Pregnant or lactating women. 
 
Women of childbearing age, who do not ensure a hormonal contraceptive method or 
intrauterine device during the study period or without a history of bilateral tubal 
obstruction, oophorectomy or hysterectomy; as fertile age we understand women who 
have not had their menopause, defined as 12 months since the last menstruation in women 
over 40 years. 
 
Subjects with participation in clinical research studies 90 days prior to inclusion in the 
present study. 
 
Diagnosis of liver disease or elevation to three times the normal upper value of any of the 
following liver enzymes: aspartate transferase (AST), alanine transferase (ALT) or bilirubin. 
 
Inability to attend or answer the evaluations made in each of the visits. 
 
Positive smoking (specified as cigarette consumption regardless of amount and frequency) 
 
Positive alcoholism (specified as the consumption of alcoholic beverages, regardless of 
quantity and frequency, during the study intervention period). 
 
Contact lens users. 
 
Occlusible iridocorneal angle, defined as a trabecular mesh visible in less than 90 ° of the 
angular circumference to gonioscopy. 
6.2.3 Elimination criteria 
 
 
Withdrawal of the consent letter under information. 
 
Presentation of a serious adverse event. 
 
No tolerability or hypersensitivity to any of the compounds used during the tests 
(fluorescein, green lysine, tetracaine) 
 
No tolerability or hypersensitivity to any of the investigational drugs. 
 
Adherence <50% determined by the diary of the subject, of the established dose of the 
pharmacological intervention in any of the visits. 
6.2.4 Identification of the subject 
 
The patients of the study will be identified by a number and the initials of their name. 
 
The initials of the study subject will be obtained starting with the first letter of the name, followed 
by the first letter of the first surname and the first letter of the second surname, obtaining maximum 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 21 of 63 
 
three letters, in case the person has two names or a compound surname the first letter will always 
be used. 
Example: 
1. Arieh Daniel Mercado Carrizalez 
a. Iniciales: AMC 
2. Juan De la Torre Orozco 
a. Initials: JDO 
 
In the counting stage, the participant number will be assigned consecutively, using 3 consecutive 
digits. Once the subject has been selected, he will be assigned a number with which he will be 
identified throughout the study. Said code will be composed of eight numbers in the following order 
from left to right: 
• 
three digits of the molecule under study according to the denomination by the sponsor. 
• 
two digits corresponding to the research center number. 
• 
three digits of the number consecutive to its inclusion assigned in the research center. 
Example: 
 
6.3 Intervention 
6.3.1 Managed treatments 
6.3.1.1 Treatment under study 
The characterization and stability tests of the treatment under study are issued by Sophia 
Laboratories , S.A. of C.V and will be found in the certificates contained within the master folder of 
the study. 
More detailed information can be found in the researcher's manual. 
 
- 
PRO-174  
o Active substance: Levofloxacin 0.5% 
o Pharmaceutical form: ophthalmic solution 
o Prepared by: Sophia Laboratories, S.A. of C.V 
o Dosage: 1 drop in both eyes, 8 times a day during the waking period 
o Description of the solution: transparent solution, free of visible particles. 
o Description of container: sterile multi-dose bottle 
 
 
 
 
 
174-01-001 
Molecule key 
Center number 
Inclusion  
number 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 22 of 63 
 
Table 4. Quali-quantitative formulation of PRO-174 
Type of agent 
Amount mg/mL 
Function 
Levofloxacin hemihydrate (1) 
5.0 
Active principle  
Sodium Citrate Dihydrate 
Without showing 
Additive 
Citric acid monohydrate 
Without showing 
Additive 
Disodium Edetate Dihydrate 
Without showing 
Additive 
Sodium chloride 
Without showing 
Additive 
Benzalkonium Chloride (2) 
0.1 
Additive 
Fumante Hydrochloric Acid (3) 
Without showing 
Additive 
Sodium Hydroxide (4) 
Without showing 
Additive 
Water for preparation of 
injectables c.b.p.(5) 
1.0 ml 
Vehicle 
Quali-quantitative formulation of the product under investigation PRO-174. The concentration of the active ingredients 
is shown, as well as the substances that act as an additive. 
OBSERVATIONS: 
(1) Equivalent to Levofloxacin (adjustment made by power). 
(2) 50% solution. 
(3) 4N hydrochloric acid solution. 
(4) 4N sodium hydroxide solution. 
(5) c.b.p. (how much is enough for). 
 
6.3.1.2 Reference treatment 
As the reference treatment, a commercially available medication, your batch number and IPP will 
be kept as proof of the characterization of said product. 
- 
Sophixín Ofteno® 
o  
o Active substance: Ciprofloxacin 0.3% 
o Pharmaceutical form: Ophthalmic solution 
o Prepared by: Sophia Laboratories, S.A. of C.V 
o Dosage: 1 drop in both eyes, 8 times a day during the waking period 
o Description of the solution: transparent solution, free of visible particles. 
o Description of container: sterile multi-dose bottle 
 
 
 
 
 
 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 23 of 63 
 
Table 5. Sophixin Ofteno quali-quantitative formulation 
Type of agent 
Amount mg/mL 
Function 
Ciprofloxacin(1) 
3.0 
Active principle 
Boric acid 
Without showing 
additive 
Benzalkonium Chloride (2) 
0.22 
additive 
Sodium chloride 
Without showing 
additive 
Disodium edetate dihydrate 
Without showing 
additive 
Water 
for 
injection 
preparation c.b.p.(3) 
1.0 ml 
vehicle 
Quali-quantitative formulation of Sophixín Ofteno®. The concentration of the active ingredients is shown, as well as 
the substances that act as an additive. 
OBSERVATIONS: 
(1) It is added as Ciprofloxacin Monohydrate. 
(2) 50% solution. 
(3) How much is enough for. 
(4) 4N sodium hydroxide solution. 
(5) c.b.p. (how much is enough for). 
 
6.3.2 Strategies to improve adherence and procedure to monitor adherence 
1. 1. Direct questioning by the PI about the application of the intervention. 
2. 2. Depending on the IP, messages can be sent or reminder calls can be made. 
3. 3. Delivery of a printed chronogram specifying the date of the visit and its activities 
4. 4. Review on each visit of the subject's diary.  
6.3.2.1 Procedure to monitor adherence 
Adherence monitoring will be done in the research center through the diary of the subject, will be 
done as follows: 
𝐴𝑑= (𝐴𝑟)100/𝐴𝑖 
Ad = Adherencie 
Ar = Registered applications 
Ai = Applications indicated for the intervention 
This result will allow the PI to determine if the subject continues in the study according to the 
stipulations of the elimination criteria. 
6.3.2.2 Procedure to determine adherence 
The final adhesion will be determined by the sponsor by means of the weight of the bottle. 
Before delivering the medication to the research center, the weighing of the bottles to be delivered 
must be carried out. After the return of the medication by the center will be weighing. The weighing 
will be carried out according to the procedures regulated by the sponsor. 
The adhesion will be calculated considering: the weight of the empty bottle, the weight of the drop, 
the weight of the bottle with the content, the calculation of the total of drops to be applied during 
the entire time of intervention and the total weight of the drops applied. The following simplified 
formula will be used: 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 24 of 63 
 
𝐴𝑑= (𝑃𝑖−𝑃𝑓)100
𝑃𝑇
 
Where: 
Ad = adhesion 
P_i = weight of the bottle delivered to the subject at the start 
P_f = weight of the bottle returned by the subject 
P_T = weight of the posology indicated for the intervention. 
 
𝑃𝑇= (𝑃𝑔)𝐺 
Where: 
P_g = weight of the drop of the intervention, determined by the department of research and 
development 
G = number of drops indicated for the intervention. 
 
6.3.3 Treatments and concomitant interventions allowed and prohibited during the study 
 
The use of concomitant medications by any route of administration during the intervention period 
will not be allowed. Except those specified for the study procedures. The objective of this restriction 
is to avoid pharmacological interactions that could alter the results of the evaluated variables. 
6.3.4 Treatment management 
The interventions will be provided by Sophia Laboratories, S.A. of C.V, for each research center. They 
will be labeled, reconciled and weighed previously. The handling of the treatment will be under the 
responsibility of the researcher or a designated member of his team.  
6.3.4.1 Delivery and reception 
The delivery will be made in closed cardboard boxes by means of a courier service or directly by the 
sponsor's staff to the address of the research center according to the study plan. 
The reception will be exclusively carried out by the research center team, including the researcher. 
You must check the good condition of the primary packaging (box). In the event that it shows 
alterations or defects in its integrity that from its judgment could have damaged the content, it 
should report it to the sponsor. If the package does not show significant defects, it will proceed to 
open it.  
Inside you must locate the acknowledgment document and the logger (data logger) of temperature 
and humidity. You should check that the registered temperature and humidity comply with the 
specifications for transport and shelter (see section 6.3.4.2 Storage). Verify the content 
(interventions) with what is reported in the document. In case the document corresponds to the 
content, it will sign the receipt and send it to the sponsor. Otherwise, notify the sponsor. 
In the study center, the personnel assigned by the IP will deliver to the inpatients the corresponding 
treatment, sufficient to complete the indicated applications. The center must register the medicine 
delivered. 
 
6.3.4.2 Storage 
The medication must be stored in a secure area with restricted access. 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 25 of 63 
 
It should be stored at room temperature at <30º Celsius. 
The research center has the obligation to record, in the format designated by the sponsor, the 
temperature and humidity registered in the data logger. This record should include the current 
temperature and humidity, as well as the minimum and maximum of each of these. It must be done 
at least once a day, on business days. 
Said data will be compared by the clinical monitor according to the registration in the data logger.    
6.3.4.3 Return 
The research subjects will return to the personnel indicated by the IP in the center their treatments 
in the final visit. The refund will be made by the research center when the sponsor indicates it. Prior 
to the return the research center must make a count of the assigned medication and the remaining 
medication, with the aim of creating an inventory which serves for the final filling of the medication 
return form. 
6.3.5 Overdose 
Overdosage with PRO-174 or Sophixin Ofteno® is not likely to cause effects that threaten function, 
the organ or less, life. The above, because increasing the number of drops instilled in an application 
will not increase the exposure to the drug, since the lacrimal lake does not have the capacity to 
contain a volume greater than one drop, spilling the rest. In case of increasing the frequency of 
instillations, an increase in the incidence of adverse reactions could be seen (eg, foreign body 
sensation, headache, photophobia, etc). 
For purposes of this protocol we understand as overdosage the increase in 25% of the indicated 
instillations. That is, 10 or more applications per day on days 1 and 2, or 5 or more applications on 
days 3 to 7. 
1. The report of the overdose will be made in the following tenor: 
2. How a deviation to the protocol. The regime instructed in the protocol was not followed. 
3. How an EA. Only if it is associated with signs and symptoms. 
4. How an EAS. If you meet the criteria to be classified as an EAS. 
 
6.4 Outcome variables 
6.4.1 Security variables 
6.4.1.1 Primary outcome variables 
 
Presence of adverse events. 
 
Intraocular pressure. 
 
Visual ability 
 
Laboratory tests: BHc, QS and PFH. 
 
Ocular surface staining with fluorescein and lissamine green using the Oxford scale. 
 
Ophthalmological signs: conjunctival hyperemia, chemosis. 
6.4.1.2 Primary outcome variables of tolerability Ardor 
 
 
Foreign body sensation 
 
Itching 
 
Eye comfort index. 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 26 of 63 
 
6.4.1.3 Secondary outcome variables 
 
Rupture time of the tear film 
 
Life signs: FC, FR, TAS. 
 
Posterior segment 
 
 
6.4.2 Efficacy variables. 
 
6.4.2.1 Primary outcome variables 
It does not apply because it is a phase I study. 
 
6.4.2.2 Secondary outcome variables 
It does not apply because it is a phase I study. 
 
6.4.3 Methods and scales to be used for the measurement of the variables 
 
 
Variable 
Unity 
Symbol 
Type 
Measuring method 
Normal value 
Age 
Years 
-- 
Continuous 
Calculation from the 
date of birth 
NA 
Gender 
Female/ Male 
F / M 
Nominal 
Direct questioning 
NA 
Adverse events 
Number of cases 
n 
Discreet 
Count 
NA 
Intraocular 
pressure 
Milimeters of 
mercury 
mmHg 
Continuous 
Goldman´s 
applanation 
tonometry 
11 - 21 
Visual ability 
Fraction 
Snellen 
Nominal 
Primer 
 
Tear rupture time 
Seconds 
s 
Continuous 
Direct count 
> 10   
Eye comfort index 
points 
-- 
Discreet 
Questionnaire 
 
Adverse events 
Present / Absent 
-- 
Nominal 
Comprehensive 
valuation 
Absent 
Vital signs 
Heart rate 
Beats per minute 
lpm 
Discreet 
Auscultation 
60 – 100 
Breathing 
frequency 
Breaths per minute 
rpm 
Discreet 
Auscultation 
12 – 24 
Systemic blood 
pressure 
Milimeters of 
mercury 
mmHg 
Continuous 
Non-invasive 
auscultatory 
measurement 
< 120 / 80 
Previous segment 
Ocular surface 
staining 
Degrees 
-- 
Discreet 
Direct observation 
with fluorescein and 
green lysamin stain 
Oxford Scale 
Ophthalmologic signs and symptoms 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 27 of 63 
 
Variable 
Unity 
Symbol 
Type 
Measuring method 
Normal value 
 
Conjunctival 
hyperemia 
Normal / Very Light 
/ Mild / Moderate / 
Severe 
 
 
-- 
Ordinal 
Direct observation. 
Classification of Efron. 
Normal 
Chemosis 
Present / Away 
 
-- 
Nominal 
Direct observation 
Absent 
Burning 
Severity: Absent, 
very mild, mild, 
moderate and 
severe 
 
-- 
Nominal 
Direct questioning 
Absent 
Foreign body 
sensation 
Severity: Absent, 
very mild, mild, 
moderate and 
severe 
 
 
-- 
Nominal 
Direct questioning 
Absent 
Pruritus 
Frequency: At all 
times, almost at all 
times, 50% of the 
time, almost in no 
time, at any time 
 
 
-- 
Nominal 
Direct questioning 
Absent 
Posterior segment 
 
Macula 
Normal / Abnormal 
 
-- 
Nominal 
Direct observation 
Normal 
Optical disk 
integrity 
Normal / Abnormal 
-- 
Nominal 
Direct observation 
Normal 
Blood count 
 
 
Erythrocytes 
 
M/uL 
Continuous 
 
 
Hemoglobin 
Grams over deciliter 
g/dL 
Continuous 
 
 
Hematocrit 
Percentage 
% 
Continuous 
 
 
VGM 
Femto liters 
fL 
Continuous 
 
 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 28 of 63 
 
Variable 
Unity 
Symbol 
Type 
Measuring method 
Normal value 
HCM 
picograms 
pg 
Continuous 
 
 
CMHbG 
Grams over deciliter 
g/dL 
Continuous 
 
 
Leukocytes 
Thousands per liter 
units 
Mil/uL 
Continuous 
 
 
Platelets 
Thousands per liter 
units 
Mil/uL 
Continuous 
 
 
Myelocytes 
Percentage 
% 
Discreet 
 
 
Metamyelocytes 
Percentage 
% 
Discreet 
 
 
Bands 
Percentage 
% 
Discreet 
 
 
Segmented 
Percentage 
% 
Discreet 
 
 
Lymphocytes 
Percentage 
% 
Discreet 
 
 
Monocytes 
Percentage 
% 
Discreet 
 
 
Eosinophils 
Percentage 
% 
Discreet 
 
 
Basophils 
Percentage 
% 
Discreet 
 
 
Blastos 
Percentage 
% 
Discreet 
 
 
Blood chemistry 
Glucose 
Milligrams on 
deciliter 
mg/dL 
Continuous 
 
 
Urea 
Milligrams on 
deciliter 
mg/dL 
Continuous 
 
 
Creatinine 
Milligrams on 
deciliter 
mg/dL 
Continuous 
 
 
Liver function tests 
Alanine transferase 
Units on liter 
U/L 
Continuous 
 
 
Aspartate 
transferase 
Units on liter 
U/L 
Continuous 
 
 
Total bilirubin 
Milligrams on 
deciliter 
mg/dL 
Continuous 
 
 
Direct bilirubin 
Milligrams on 
deciliter 
mg/dL 
Continuous 
 
 
Indirect Bilirubin 
Milligrams on 
deciliter 
mg/dL 
Continuous 
 
 
 
 
 
Table 6. Scales to be used 
 
The following describes the methods and scales that will be used for the measurement of the 
variables, which are in strict alphabetical order: 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 29 of 63 
 
6.4.3.1 Visual ability 
Visual acuity (VA) is a test of visual function. Spatial visual acuity is the ability to distinguish separate 
elements of an object and identify them as a whole. It is quantified as the minimum separation angle 
(located at the nodal point of the eye) between two objects that allows perceiving them as separate 
objects. 
Snellen's notation is described as the distance at which the test is performed, divided by the distance 
at which the letter is vertically equivalent to 5 arc minutes. Thus, at 6 meters a letter 6/6 (20/20) 
equals 5 minutes of arc, a letter 6/12 (20/40) equals 10 minutes, and a letter 6/60 (20/200) equals 
50 minutes The Snellen fraction can also be expressed as a decimal (ie 20/20 = 1 and 20/40 = 0.5). 
[26] 
The VA will be evaluated basally, without refractive correction with the Snellen chart. Which will be 
located in a place with adequate lighting, natural or artificial and at a distance of 3m from the subject 
to be evaluated. The visual acuity of each eye will be taken, starting with a right eye (DO) asking the 
subject to keep both eyes open and using an occluder to cover the left eye (OS); the subject will 
read aloud the lines that the evaluator points out, the line of smaller letters that he reaches to see 
will be annotated by the fractional evaluator as the DO of the DO in the clinical record. Proceed to 
the OS with the same method. 
Subsequently the best refractive correction of the subject will be made and the examination will be 
repeated using the obtained refraction. This result will be reported as CV, it will be written in fraction 
in the clinical file and in the CRF, in addition in the CRF it will be written in decimal. By definition, 
the CV can not be inferior to the AV. 
 
6.4.3.2 Eye comfort index 
It is a questionnaire designed to measure the irritation of the ocular surface with Rasch analysis to 
produce estimates on a linear scale of intervals (ratings: 0-100). Similar to the index for ocular 
surface diseases, the ocular comfort index (ICO) evaluates symptoms. The ICO contains 8 items (one 
positive and eight negative) that focus on the discomfort associated with alterations of the ocular 
surface. Each of these questions has two parts, which inquire separately the frequency and severity 
of the symptoms. [27] See annex 13.1 Index of ocular comfort 
The evaluator will deliver the questionnaire to the subject and allow the subject to answer it calmly 
without any pressure and / or coercion, will only assist him if he has difficulty understanding any of 
the questions. 
6.4.3.3 Eye surface integrity:  
This will be done by means of biomicroscopy using the slit lamp of the research center. A full 
assessment of the previous segment will be made, which will be recorded in the clinical file. The 
lighting techniques used will be at the discretion of the IP. 
The variables that will be registered in the CRF in this protocol, and correspond with the variables, 
are:  
- Conjunctival hyperemia. 
It is defined as the simplest reaction of the conjunctiva to a stimulus, a red appearance 
secondary to the vasodilation of the conjunctival vessels of variable intensity. He will 
graduate using the Efron scale. [28] See annex 13.2 Efron scale for conjunctival hyperemia 
- Chemosis. 
It is defined as conjunctival edema, the result of an inflammatory reaction. It is qualified as 
present or absent. The evaluator will use a narrow beam of light at 60 ° and will measure if 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 30 of 63 
 
the conjunctiva separates from the sclera at ≥ 1/3 of the total palpebral opening or if it 
exceeds the gray line. [29]  
6.4.3.3.1 Stains 
• Staining with green lysine. 
A drop of topical anesthetic will be instilled in the conjunctival cul-de-sac, then a second drop will be 
applied to the tip of the strip of green lysine and it will be allowed to slip towards the bottom of the 
sac. It is essential to quickly evaluate the staining, in sequence, first in the DO and then the OS, so 
that the observed patterns are equally bright. [30] See Annex 13.3 Oxford Scale 
• Fluorescein staining. 
A drop of topical anesthetic will be instilled into the conjunctival cul-de-sac, then a second drop will 
be applied to the tip of the fluorescein strip and it will be allowed to slip to the bottom of the sac. It 
is essential to quickly evaluate the staining, in sequence, first in the DO and then the OS, so that the 
observed patterns are equally bright. This valuation will be made with the cobalt blue filter. [30] See 
Annex 13.3 Oxford Scale 
For both stains, the value obtained according to the Oxford scale will be registered in the CRF. 
6.4.3.4 Presence of adverse events 
The management of the EAs will be done according to what is described in section 9.3 Adverse 
events 
The PI will register in the corresponding section of the CRF the EAs that come to present the subjects 
of the study in addition to referring it in its essential document. 
6.4.3.5 Intraocular pressure 
Tonometry is the objective measure of IOP, based primarily on the force required to flatten the 
cornea or the degree of corneal indentation produced by a fixed force. Goldman's tonometry is 
based on the Imbert-Fick principle. [26] Tonometry will be performed, after instillation of a drop of 
topical anesthetic (tetracaine 0.5%), with fluorescein and the use of cobalt blue filter (after 
evaluation of corneal surface staining). There will be 3 shots, which will be recorded in the clinical 
file and the average will be registered in the CRF. 
6.4.3.6 posterior segment 
The evaluation of the posterior segment will be carried out under medication mydriasis (tropicamide 
0.8% / phenylephrine 5%), in the slit lamp with an aerial loupe (at the choice of the PI). An integral 
assessment of the fundus (including optic disk, posterior pole and periphery) will be performed in 
search of abnormalities that alter the study result. Prior to mydriasis medicamentosa, the evaluation 
of the iridocorneal angle should be counted, in order to rule out an occludable angle, which is 
defined as a posterior trabecular mesh visible in less than 90 ° of the angular circumference. [31] 
[32] The result of the assessment will be recorded in the clinical file. The CRF will record the 
assessment of the macula and optic nerve as normal, abnormal or abnormality that does not affect.  
6.4.3.7 Vital signs 
The vital signs to be evaluated (FC, FR and TAS) can be measured by an assistant duly indicated in 
the organization of the center and the delegation of responsibilities, the technique to be used for 
the FC and FR will be with the count of repetitions in one minute by direct auscultation with 
stethoscope. 
The SBP should be measured with 5 minutes of previous rest, in the left arm. The instrument can be 
manual or automatic according to the IP. It is necessary that all measurements are equal in 
circumstances. 3 measurements will be made, with a minimum interval of 5 minutes between them. 
The IP will record the average in the note and the CRF. 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 31 of 63 
 
6.4.3.8 Ocular symptomatology 
The subject will be questioned directly about the presence in general (since the last visit) of the 
following symptoms: burning, foreign body sensation and pruritus. Respond about the severity and 
frequency of symptoms such as: 
Severity: Absent (0), very mild (1), mild (2), moderate (3) and severe (4) 
Frequency: At all times (4), almost at all times (3), 50% of the time (2), almost at no time (1), at any 
time (0). 
The number corresponding to each symptom will be registered in the CRF. 
6.4.3.9 Breaking time of the tear film 
One of the first aspects of the tear film that changes when there is an alteration to the ocular 
surface, is its stability. In general, if the corneal or conjunctival surface is damaged, it is unlikely that 
a stable tear film can be maintained. 
The most common method to evaluate the stability of the tear film is the evaluation of TRL with 
fluorescein. Once the fluorescein is instilled, with the cobalt blue filter the patient is asked not to 
blink. The precorneal colored fluorescein layer will change to less fluorescent or non-fluorescent 
regions. The time that elapses from the last blink until the appearance of these regions is the TRL. It 
will be reported in seconds, in the clinical file and in the CRF. 
6.4.3.10 Pregnancy test 
It refers to the performance of a rapid pregnancy test in all women of childbearing age who wish to 
enter the study. By fertile age we understand women who have not had their menopause, defined 
as 12 months since the last menstrual period in women over 40 years of age; or those who 
underwent bilateral hysterectomy or oophorectomy. Women of childbearing age with 
contraceptive methods including bilateral tubal obstruction should be tested for pregnancy. This 
test will be carried out by the IP or the designated team person according to the instructions of the 
device delivered by the sponsor. When applicable, the completion, result and date must be 
registered in the CRF. If you do not apply, you must write down the reason. 
6.4.3.11 Lab tests. 
The PI will deliver to the subject the order of the studies of BH, QS and PFH, to be carried out in the 
clinical laboratory designated by the sponsor. The clinical laboratory will deliver to the IP the results 
for its assessment and registration. The normal parameters to be considered will be the ranges 
established by the laboratory, Nevertheless the clinical criterion of the PI will prevail in the decision 
of normality or abnormality of the results. 
6.4.4 Measurement time 
The measurements of the variables of primary and secondary outcome will be made and evaluated 
for each visit, according to the following: 
Visit scrutiny / Day 0 – X 
This visit, by definition, must precede the baseline visit. There is no minimum period to be observed 
between the scrutiny visit and the baseline, it will depend on having the results of the laboratory 
tests; notwithstanding, the period between these visits should not exceed 10 days. 
Some of these measurements should be complemented with those of the baseline visit and thus 
meet the eligibility criteria (see Schedule and study diagram), at the discretion of the IP. 
 
1. Laboratory sample taking. 
2. Visual ability 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 32 of 63 
 
3. Intraocular pressure.Índice de confort ocular 
4. Evaluation of ocular signs and symptoms 
5. Integrity of ocular surface 
to. Epithelial defects (TF and TVL) 
6. TRL 
7. Subsequent segment evaluation. 
8. Vital signs 
9. Evaluation of adverse events 
Basal Visit / Day 0. 
Some of these measurements will be taken at the screening visit to complete the eligibility criteria 
(see Schedule and study diagram), at the discretion of the PI, they may be taken to complete the 
baseline visit data. 
 
1. Visual ability 
 
2. Intraocular pressure. 
 
3. Eye comfort index 
 
4. Evaluation of ocular signs and symptoms 
 
5. Integrity of ocular surface 
 
 
a. Includes stains 
 
6. TRL 
 
7. Subsequent segment evaluation. 
 
8. Vital signs 
 
9. Evaluation of results of laboratory tests 
 
10. Evaluation of adverse events 
Visit 1 / Day 3.  
It can be done in a period ± 1 day in relation to day 3 of application. 
1. Visual ability 
2. Intraocular pressure. 
3. Evaluation of ocular signs and symptoms 
4. Integrity of ocular surface 
 
a.Includes stains 
5. TRL 
6. Vital signs. 
7. Evaluation of adverse events. 
 
Final  visit/ Day 8.  
If the visit can not be made on the 8th, it can be done within a period of up to two days, that is, on 
the 9th or 10th day. Not before, since the application of the medication will not be completed as 
dictated the protocol. 
 
 
1. Visual ability 
2. Intraocular pressure. 
3. Eye comfort index 
4. Evaluation of ocular signs and symptoms 
5. Integrity of ocular surface 
a. Includes stains 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 33 of 63 
 
6. TRL 
7. Subsequent segment evaluation. 
8. Vital signs. 
9. 9. Evaluation of adverse events. 
Security call / Day 12.  
It can be done in a period ± 1 day in relation to day 12 of the start of application. 
1. Ask about the presence of an adverse event. 
2. Evaluation of results of laboratory tests 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 34 of 63 
 
6.4 
Timeline and study diagram 
Procedures 
Scrutiny 
Basal Visit 
Visit 1 
Final Visit 
Call Security 
 Day 0 -X 
Day 0 
Day 3 ± 1 
Day 8 a +2  
Day 12 ± 1 
CI Signature 
X 
 
 
 
 
Clinic history 
X 
 
 
 
 
Ophthalmological clinical history 
X 
 
 
 
 
Laboratory sample taking 
X 
 
 
X 
 
Laboratory tests review 
 
X 
 
 
X 
Pregnancy test 
X 
 
 
X 
 
Eligibility criteria 
X 
Xa 
 
 
 
Assignment 
 
X 
 
 
 
Delivery 
of 
intervention 
and 
indication 
of 
starting 
the 
application the next day day 1. 
 
X 
 
 
 
Return of intervention 
 
 
 
X 
 
Adherence evaluation 
 
 
X 
X 
 
Adverse events 
X 
X 
X 
X 
X 
Intraocular pressure 
X 
X1 
X 
X 
 
Visual ability 
X 
X1 
X 
X 
 
TRL 
X 
X1 
X 
X 
 
Eye surface integrity 
X 
X1 
X 
X 
 
Eye symptoms 
X 
X1 
X 
X 
 
posterior segment 
X 
X1 
 
X 
 
Vital signs 
X 
X1 
X 
X 
 
Ocular Comfort Index 
 
X 
 
X 
 
Daily delivery of the subject 
 
X 
X 
 
 
Return 
/ 
Evaluation 
of 
the 
subject's Journal 
 
 
X 
X 
 
Continuity 
evaluation 
of 
the 
subject 
 
 
X 
 
 
a Eligibility criteria will be completed with the review of laboratory tests 
1 These measurements may be taken from the result of the scrutiny visit, if it does not exceed 10 days 
previous. It is the prerogative of the IP to decide whether to repeat the measurements at the baseline visit. 
 
 
6.5.1 Procedures to be performed per visit 
6.5.1.1 Scrutiny visit 
▪ 
Signature of informed consent: refers to the signing of the written informed consent 
document. See 10.3 Consent. 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 35 of 63 
 
▪ 
General and ophthalmological clinical history: refers to the technical, clinical and legal 
document in which the patient's health conditions, medical acts and other procedures 
performed on the patient are recorded chronologically. It includes the anamnesis and 
comprehensive ophthalmological exploration that allows to discern the patient's eligibility. 
If the patient is taken from the established consultation of the study center, he / she will be 
able to use the existing clinical history, only having to perform an update. 
▪ 
Taking laboratory samples: see 6.4.3.11 Laboratory tests. 
▪ 
Pregnancy test: see 6.4.3.11 6.4.3.10 Pregnancy test. 
▪ 
Eligibility criteria: refers to the review by the IP, where it states that the subject can be 
included in the study by meeting the inclusion criteria and not meeting the exclusion 
criteria. See 6.2 Eligibility criteria 
▪ 
Intraocular pressure: see 6.4.3.5 Intraocular pressure 
▪ 
Visual ability: see 6.4.3.1 Visual capacity 
▪ 
TRL: see 6.4.3.9 Rupture time of the tear film 
▪ 
Integrity of ocular surface: see 6.4.3.3 Integrity of ocular surface: 
▪ 
Eye symptoms: 6.4.3.8 Ocular symptomatology 
▪ 
Subsequent segment: see 6.4.3.6 Subsequent segment 
▪ 
Vital signs: see 6.4.3.7 Vital signs 
▪ 
Adverse events: see 6.4.3.4 Presence of adverse events6.5.1.2 Visita basal 
▪ 
Review of laboratory tests: refers to the review and analysis by the IP of the results of the 
BH, QS and PFH. See 6.4.3.11 Laboratory tests. 
▪ 
Eligibility criteria: with the laboratory results, the subject's profile will be finalized for 
inclusion or not. 
▪ 
Assignment: It refers to determining the intervention that the patient will follow during the 
study. It will be done according to section 7. Methods. Assignment of the intervention. This 
assignment will be made at the baseline visit (day 0) and will go along with the indication to 
start the treatment period the next day (day 1). 
▪ 
Delivery of intervention: Refers to the delivery of the product under investigation to the 
patient of the study, by the research center. It will be done according to sections 6.3.1 
Managed treatments and 6.3.4.1 Delivery and reception. 
▪ 
Evaluation of variables: The data of the evaluation of the variables listed below can be taken 
from the scrutiny visit, as long as it does not exceed 7 days prior to this visit. It is the IP's 
prerogative to decide whether to use the information from the screening visit or to repeat 
the evaluations on this visit. 
o Intraocular pressure 
o Visual capacity 
o TRL 
o Integrity of ocular surface 
o Eye symptoms 
o Subsequent segment 
o vital sign 
▪ 
Eye comfort index: see 6.4.3.2 Eye comfort index 
▪ 
Delivery of the subject's diary: It refers to the delivery by the IP to the subject, the subject's 
daily instrument. 
▪ 
Adverse events: see 6.4.3.4 Presence of adverse events  

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 36 of 63 
 
6.5.1.3 Visita 1 
▪ 
Evaluation of adherence: refers to the assessment made by the IP according to section 
6.3.2.1 Procedure to monitor adherence 
▪ 
Adverse events: see 6.4.3.4 Presence of adverse events 
▪ 
Intraocular pressure: see 6.4.3.5 Intraocular pressure 
▪ 
Visual ability: see 6.4.3.1 Visual capacity 
▪ 
TRL: see 6.4.3.9 Rupture time of the tear film 
▪ 
Integrity of ocular surface: see 6.4.3.3 Integrity of ocular surface: 
▪ 
Eye symptoms: 6.4.3.8 Ocular symptomatology 
▪ 
Vital signs: see 6.4.3.7 Vital signs 
▪ 
Submission of the subject's diary: see 6.5.1.2 Baseline visit 
▪ 
Return / daily evaluation of the subject: refers to the delivery of the subject's diary to the IP 
by the subject. The PI will review the diary to assess its correct filler, evaluate postinstilation 
symptoms and record applications. 
▪ 
Continuity assessment of the subject: refers to the determination by the IP and desire of 
the subject to continue with their participation in the study. 
6.5.1.4 Final Visit 
▪ 
Laboratory sample taking: ver6.4.3.11 Laboratory tests 
▪ 
Pregnancy test: see 6.4.3.10 Pregnancy test 
▪ 
Return of intervention: see 6.5.1.3 Visit 1. 
▪ 
Evaluation of adherence: refers to the assessment made by the IP according to section 
6.3.2.1 Procedure to monitor adherence 
▪ 
Adverse events: see 6.4.3.4 Presence of adverse events 
▪ 
Intraocular pressure: see 6.4.3.5 Intraocular pressure 
▪ 
Visual ability: see 6.4.3.1 Visual capacity 
▪ 
TRL: see 6.4.3.9 Rupture time of the tear film 
▪ 
Integrity of ocular surface: see 6.4.3.3 Integrity of ocular surface: 
▪ 
Eye symptoms: 6.4.3.8 Ocular symptomatology 
▪ 
Subsequent segment; see 6.4.3.6 Subsequent segment 
▪ 
Vital signs: see 6.4.3.7 Vital signs 
▪ 
Eye comfort index: see 6.4.3.2 Eye comfort index 
▪ 
Return / daily evaluation of the subject: see 6.5.1.3 Visit 1. 
6.5.1.5 Security call 
▪ 
Adverse events: see 6.4.3.4 Presence of adverse events 
▪ 
Review of laboratory tests: see 6.5.1.2 Baseline visit 
6.5.2 Diagram of the study 
An enrollment time of 30 days is estimated for the total sample.  
 
In addition to safety, the therapeutic adherence will be evaluated and problems related to the 
procedures will be solved, should they arise. 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 37 of 63 
 
 
 
 
 
 
Figure 2. Study diagram 
6.6 Sample size 
A total size of 30 subjects is estimated, distributed in intervention groups [15 subjects (30 eyes) per 
group] 
6.6.1 Calculation of the sample size 
Although there are no references on the calculation of sample size in phase I studies, it was 
considered pertinent to perform it according to the presentation of adverse events reported by 
Schwab IR, et al, in a case-control study in 423 subjects with ophthalmic solutions of levofloxacin 
0.5 % and ofloxacin 0.3% for 5 days. [22] 
The percentage of adverse events that occurred with the preservative-free HS solution was 7.3%, 
which is why we consider that at least more than 60% of the exposed subjects will not present this 
rate of adverse events. 
The sample size was calculated using the formula for proportions 
𝑛= [(𝑝1)(𝑝2) + (𝑝1)(𝑝2) (𝑍1−𝛼
2
+ 𝑍1−𝛽)
2
]/(𝑝1 −𝑝2)2 
With a statistical confidence of 95% corresponding to the type I error, equal to 1.96, with a power 
of 80%, corresponding to the type II error, equal 0.84. 
According to the previous calculation, the result is 12.5 subjects (13) per group. The total when 
considering 2 intervention groups is 26 subjects, which was increased by 20% for the probable 
losses. The total sample size required is 30 subjects. Therefore, each group will consist of 15 
subjects, who will provide both eyes for the analysis, so that the total sample to be analyzed will be 
composed of 60 eyes.    
7 days 
Waiting for 
laboratory 
results 
Sophixín Ofteno® 
PRO-174 
Day 0 
Basal 
visit 
Day 3 
Visit 1 
Day 8 
Final 
visit 
Day 13 
Called 
security 
-1 to-10 
days 
Scrutiny 
Day 1 
Start 
application 
Day 7 
End 
li
Day 3 
Posology 
change 
+------8 times a day ------+--------------------- 4 times a day ------------------ 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 38 of 63 
 
6.7 Recruitment 
It is recommended that during the development of this research protocol, the principal investigator 
requests the approval of the Research Ethics Committee and the Research Committee, as well as 
the authorization to the relevant regulatory entity, to publish or disseminate in the mass media, the 
invitation to participate in the study to those people who meet the eligibility criteria. 
It is possible to discuss with other health professionals the opportunity for healthy subjects to be 
evaluated by an ophthalmologist at no cost, as well as cabinet exams that will allow the more 
accurate determination of their ocular clinical status by participating in a sponsored clinical research 
protocol. by Laboratorios Sophia, SA of C.V. 
 
7. Methods Assignment of the intervention 
7.1 Generation of the allocation sequence 
The random numbers will be generated through the online tool: 
 www.randomization.com 
Two strata corresponding to the intervention groups will be used, which will be balanced for a 
research center. The allocation will be 1: 1.  
7.2 Blinding mechanism 
Blinding will be performed by personnel assigned by the Clinical Operations Management of 
Laboratorios Sophia, S.A de C.V. Which will consist in the elimination of the primary label 
(commercial) in the case of Sophixín Ofteno® and the placement of a label identical to the other 
intervention. There will be a masking in the secondary packaging which will be identical for the 
interventions.   
7.3 Implementation 
The allocation sequence will be generated by personnel assigned by the Clinical Operations 
Management of Laboratorios Sophia, S.A de C.V. The research center will receive a set of envelopes 
which will contain the intervention number individually. The envelopes will be identical on the 
outside. Each of these envelopes will be shown to the participants for their election by the principal 
investigator or by a designated member of their team.  
7.4 Blinding (Masking) 
The blinding will correspond to the research subject and the principal investigator. In addition, the 
statistical analysis will be carried out in a blinded manner for the partial and final analysis. 
The masking will be done using boxes in the primary packaging identical in the two groups. Blinding 
for the research subject and the researcher will be done by replacing the commercial labels in the 
case of the comparator in the bottles and the use of identical labels that contain the assignment 
number. 
7.4.1 Opening of blinding 
Blinding may be opened in the following cases: 
 
1. Presence of a serious adverse event. 
2. Safety alarm due to the use of the drugs under study. 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 39 of 63 
 
3. In case the sponsor determines it for any security reason or other reason that it considers 
pertinent. 
 
8. Methods Collection, administration and data analysis 
8.1 Methods of data collection 
A clinical monitor will be assigned to each research center, which will be authorized to monitor, 
review, procure and ensure that the quality of the information obtained from the participants is 
reliable and trustworthy. Each monitor will schedule periodic visits to the research centers in order 
to review the source documents and corroborate the information captured in the case report format 
(CRF). All clinical monitors will be trained in relation to the information of the study protocol 
(objective, visits, procedures, range of accepted values, etc.). In the event that the data are not 
identical between the two registers, the clinical monitor will generate a discrepancy, which must be 
resolved by the research center in time that the sponsor deems reasonable to meet the objectives 
of the clinical study. The correction of the discrepancies will be made according to the Good 
Documentation Practices.  
The data registered in the CRF will be reviewed by personnel of Sophia Laboratories, S.A. of C.V 
trained in the ophthalmological, clinical and pharmacological area, which will have the power to 
generate discrepancies in the event that the data do not adhere to the stipulations of the research 
protocol or endanger the participants. 
Once all discrepancies generated by the team of clinical monitors and clinical staff have been 
resolved, the data will be downloaded into an electronic database (Excel Sheet) by personnel 
designated by the sponsor. A new review of the data will be carried out to corroborate the fidelity 
of the same and new discrepancies may be generated in case it was considered. 
The database generated will be safeguarded by the sponsor and will only have personal access 
designated by the same. 
8.1.1 Strategies to complete the follow-up 
• 
You will be clearly informed of the importance of the study and the benefits that the 
population will obtain from the results of the study. 
• 
Transportation assistance will be provided in order for the participant to attend their visits. 
• 
In case the IP deems it convenient, it can make calls or send text messages or via email to 
the research subject. The content of these must be previously approved by the ethics 
committee. 
• 
A printed calendar will be provided with the objective of reminding the participant of their 
appointments and the activities that will be carried out, in addition to the estimated 
duration of the same. 
• 
In case the participant does not attend his / her appointment, the research center must 
make a call to know the reason and try to arrange a new appointment within the established 
window period or an unscheduled appointment. 
• 
• In case it is not possible to make an appointment, it will be asked about the presence of 
adverse events and the reason for leaving the study, such as minimum data. 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 40 of 63 
 
8.2 Data management 
The subject's medical record (including clinical notes, test results, etc.), as well as the subject's diary, 
and the ICO questionnaire are considered source data. 
The IP or the designated person of your team will fill out the Case Report Format (CRF) as well as all 
other documents provided by the sponsor (for example, documents related to the handling of the 
treatment). 
A CRF was designed to record the data that are required in the protocol and that the researcher 
collects in each of the visits. 
In the case of self-assessment questionnaires, it is not permissible for the principal investigator or 
person responsible for filling in to modify what was written by the subject of the study. 
The data capture in the investigator's site will be done by the investigator or the designated person 
of his team after performing the Medical File. The researcher or a designated person of your team 
will be trained in the filling of the CRF 
All corrections to the CRF data should be made by the investigator or the designated person of your 
team in accordance with the instructions provided. 
To ensure the confidentiality and security of the data, user names and access codes will be used to 
restrict access to the system only to authorized personnel. 
The monitor must ensure that all the data has been filled in the CRF. After comparing the data 
against the source documents, in case a correction or clarification is necessary, the monitor will 
request it from the researcher; which must be answered and closed as soon as possible. 
The Scientific Committee of Laboratories Sophia, S.A. of C.V. will give the latest medical-scientific 
review, and will set the standard for freezing the database. 
8.3 Statistical methodology 
8.3.1 Analysis of primary and secondary outcome variables. 
The statistical analysis will be carried out by personnel from Sophia Laboratories, S.A. of C.V The 
statistical program SPSS version 19 (IBM Corporation, Armonk, NY, USA) will be used. 
The designated personnel will be blinded to the intervention groups. The coding will be done using 
consecutive numbers for each intervention group. 
The data will be collected and sorted in an excel sheet. Later they will be exported to the platform 
of the SPSS program. The variables will be categorized according to their nature. 
The result of the continuous quantitative variables will be presented in measures of central 
tendency: media, standard deviation and ranges. See Table 6. Scales to be used 
The normal distribution of the results will be obtained by the Kolmogorov-Smirnov test. 
The statistical analysis of the continuous quantitative variables to find significant differences (p) will 
be the following:  
• Intra-group analysis: Wilcoxon rank test. 
• Inter-group analysis: Mann-Whitney U test. 
The level of difference to consider significance will be of an alpha of 0.05 or less. 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 41 of 63 
 
The result of nominal and ordinal qualitative variables will be presented in frequencies, proportions 
and percentages. See table 1 (section 6.4.3). 
The statistical analysis to identify significant differences of the qualitative variables will be done by 
creating 2x2 contingency tables and will be done as follows:  
• Intra-group difference: McNemar test. 
• Difference between groups: test χ2 (Chi-square) of Pearson. 
The level of difference to consider significance will be of an alpha of 0.05 or less. 
For the reporting of adverse events all eyes of those participants who were randomly assigned to 
an intervention group after the baseline visit will be considered. The results will be expressed in 
number of cases (eyes). 
The final report of the results will be shown in tables or graphs, as appropriate. 
It will be considered that the investigational drug is safe and tolerable when there are no clinical 
and statistical differences in all the variables of primary outcome, with respect to its comparators. 
Those subjects who comply with an adherence greater than 60% will be included in the statistical 
analysis to meet the objective of the study. It was considered that from the minimum dose necessary 
to obtain a pharmacological effect and the presence of adverse events (exposure) is sufficient to 
fulfill the general objective of the design, according to the pharmacological characteristics of the 
product under investigation.  
8.3.2 Additional analyzes 
No additional analyzes are contemplated to those previously described. Nevertheless, these may be 
performed in the event that during the conduction of the study it is required to analyze specific 
safety aspects of any intervention, maintaining the blinding until the end of the study..  
8.3.3 Population analysis and management of missing data 
An intention-to-treat analysis will be carried out, where the data of the participants who have 
completed the final visit will be included.  
 
9. Methods Monitoring 
9.1 Data monitoring 
Monitoring visits by a site monitor from Sophia Laboratories, S.A. of C.V are intended to confirm 
that the studies sponsored by Sophia Laboratories, S.A. of C.V they are conducted in accordance 
with the ethical principles that have their origin in the Declaration of Helsinki, which are consistent 
with Good Clinical Practices and with the applicable regulatory requirements; verifying its 
continuous compliance with the protocol, amendment or amendments. The monitor will review the 
accounting records of the product under investigation, and verify that site personnel and facilities 
remain adequate to carry out the study. 
The researcher must ensure that they have sufficient time, space and qualified personnel for the 
monitoring visits. 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 42 of 63 
 
In order to carry out the monitoring review, it is mandatory to provide direct access to all source 
data and those related to the study site. The monitor will conduct a review of the CRF and a 
Verification of Source Documents (VDF). By VDF means the verification of the records in the CRF 
through its comparison with the source data that the researcher will make available for this purpose. 
Regarding the CRF, the monitor will mark in each visit the screens completed and approved in case 
of use of electronic platform. 
In accordance with the applicable regulations, Good Clinical Practices, and the procedures of Sophia 
Laboratories, S.A. of C.V The monitors of Sophia Laboratories, S.A. of C.V they will contact the site 
before the start of the study to review with the staff the protocol, the regulatory, ethical 
requirements and from Sophia Laboratories, S.A. of C.V   
Sophia Laboratories, S.A. of C.V. will monitor the study to verify, among other things, that: 
• 
The data is authentic, correct and complete. 
• 
The safety and rights of the subjects are being protected. 
• 
The study is being conducted in accordance with the currently approved protocol, any other 
study agreement, Good Clinical Practices and all applicable regulatory requirements. 
• 
 
The investigator and the head of the medical institution (when applicable) agree to allow the 
monitor to have direct access to all relevant documents. 
Study monitoring visits will be conducted at regular intervals, depending on the recruitment rate, 
under the arrangements between the investigator and the sponsor. All information related to these 
visits will be handled as strictly confidential. 
 
Upon completion or early termination of the study, the monitor will carry out site closure activities 
with the investigator or site staff, as appropriate, in accordance with applicable regulations, Good 
Clinical Practices, and Sophia Laboratory procedures. , SA of C.V. 
 
After the study is closed, the researcher must keep all study records on the site in a safe place. 
Records should be maintained to allow easy and timely recovery, when necessary (for example, in 
an audit or inspection). Sophia Laboratories, S.A. of C.V. will inform the investigator / institution the 
period of time they will have to retain these records, in order to comply with all applicable regulatory 
requirements. Nevertheless, the investigator / institution must seek the written approval of the 
sponsor before proceeding to the elimination of these records. The minimum retention time will 
satisfy the most stringent standard applicable to that site for the study, in accordance with the 
provisions of the PCBs, any institutional requirements or the applicable laws or regulations, or the 
standards / procedures of Sophia Laboratories, S.A. of C.V  
The researcher / institution must notify Sophia Laboratories, S.A. of C.V Of any change in file 
arrangements including, without limitation, the following: file in an off-site facility, ownership 
transfer of records in the event the investigator leaves the site.  
9.2 Preliminary analysis and early termination of the study.  
The partial analysis described in section 6.5 and 8.3.2 will allow the sponsor to make a decision 
about the early termination of the study in the event that the safety of the participants is 
compromised. 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 43 of 63 
 
The early termination of the study will be considered in the following cases: 
1. Presence of serious adverse events in more than 5% of the participants in each intervention 
group. 
2. The competent authority (COFEPRIS) considers it for security alerts. 
3. According to the PCBs, if the CEI considers it pertinent. 
4. The Sponsor determined it for convenience or eventualities such as: economic support, 
manufacturing errors, etc. 
5. Less recruitment to the projected.  
 
In case the decision is the early termination of the clinical study, all the research centers will be 
informed within the first 24 hours by the available communication channels. Likewise, the 
corresponding authority in each country will be informed (if applicable) and the Ethics Committees 
involved. 
Each research center has the obligation to inform the subjects that participate in the clinical study 
in a period no longer than 24 hours, after receiving the information from the sponsor. You must 
inform all the subjects involved in any phase of the study. 
The result of the preliminary evaluation will be in charge of the Clinical Operations Management 
and the Medical Management of Sophia Laboratories, S.A. of C.V., which will have the faculty to 
determine the fate of the present protocol, as they deem convenient. 
9.3 Adverse events 
9.3.1 Investigator's responsibilities 
Perform the verification of adverse events through questioning, relevant physical examination, 
assessment of evolution, as well as adequate medical and pharmacological management, resolution 
or outcome and final discharge following the definitions determined in national and international 
regulations. [33] [34] [35]  
In case of adverse events or any event that puts the health and well-being of the patients at risk, 
appropriate medical attention will be provided, either at the research site or will be referred to the 
Hospital Center with greater resolving power with which the researcher and / or researcher site 
have medical care agreement. The researcher will notify the clinical monitor of the sponsor, 
according to the times established in the national and international regulations. In the case of 
serious adverse events, notify the sponsor and record the corresponding information in the case 
report form and in turn inform the Research Ethics Committee, the Research Committee.  
The attention of the adverse events will be made according to the diagram of attention of the event 
(see Figure 3. Attention of the adverse event) 
In the final report to be drafted by the Scientific Committee of the Department of Clinical Operations 
of Sophia Laboratories, S.A. of C.V, will include the report of adverse events in compliance with 
current national and international regulations. [34] [33] 
9.3.1.1 Record of adverse events in the Case Report Form 
The registry of adverse events considers the information concerning the identification data of the 
participating patient as code, age, sex, left eye, right eye. 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 44 of 63 
 
Information about the type of adverse event, adverse reaction or suspected adverse reaction to the 
product under investigation or to the study medication, as appropriate. The date on which the 
adverse event occurs is reported, as well as in which the Investigator is aware of it, date of resolution 
or outcome, as applicable. The clinical diagnosis is indicated. Include in concomitant medications 
the therapy used for the pharmacological management of the adverse event, suspected adverse 
reaction, adverse reaction. Record the outcome or resolution of the event: patient recovered 
without sequelae, with sequelae, not recovered. Patient who presented death due to adverse 
reaction / adverse event, patient who presented death and it is judged that the drug could have 
contributed, patient who presented death and this is not related to the investigational product or 
drug, or indicate that it was not knows what the consequence of the event is.  
Consign information about the product or drug under investigation or the drug associated with the 
adverse event, adverse reaction or suspected adverse reaction. As applicable, information 
concerning generic denomination, distinctive denomination or product code in research and / or 
investigational medication should be recorded, as appropriate according to the methodological 
design of the study, this is relevant in the case of blinded studies or those where they use placebo 
as comparators, since there are circumstances that justify opening the cecum to determine if the 
adverse event, the adverse reaction or suspected adverse reaction may be attributable to the active 
agent, the combination of active agents, or the substance (s). s) pharmacologically inert (s), such as 
vehicles or additives, as appropriate to the clinical research phase in which the development of the 
drug is located. It will also be necessary to record the data concerning the batch number, 
manufacturer laboratory, expiration date, dosage, route of administration, start and end dates of 
administration and / or consumption, reason for the prescription; according to whether it is a 
product or investigational medicine (protocol in which the patient currently participates) or is a 
medicine that the subject under investigation consumes for the treatment of basic concomitant 
diseases or used for the management of any sign or transient symptom that does not correspond 
to the Natural History of the pathology that motivated its entry into the research protocol.  
Record the withdrawal or maintenance of the medication, investigational product or investigational 
medication, as appropriate. Indicate if the adverse event disappears when the investigational 
product or investigational medication or suspicious medication is removed (to provoke the event). 
Also indicate if a dose adjustment is made, if the event changes in terms of intensity or seriousness, 
persistence of the reaction. It is important to indicate that in those patients who are exposed again 
to the investigational product, investigational medication or medication, which had previously been 
suspended, if the adverse reaction or adverse event reappears. 
Regarding concomitant pharmacotherapy. Indicate the generic name, the dose, the route of 
administration, start and end dates of its use, as well as the reason for the prescription regardless if 
it is consistent with the information to prescribe or technical data sheet or is used outside the 
regulations or of what the local, national or international regulatory entity has authorized. 
 
Concerning the relevant clinical antecedents. The analysis of the adverse event, adverse reaction or 
suspicion of adverse reaction considers the information previously reported, notwithstanding the 
clinical context in which said harmful phenomenon occurs in the participants of the clinical research 
protocol, it is of special interest, so that the information about previous ailments, hypersensitivity 
or allergy phenomena, previous surgical procedures, laboratory analysis or cabinet exams that have 
been practiced on the participant, etc., that the researcher deems convenient to mention may do 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 45 of 63 
 
so. If you have enough space in the case report format, you can complement the information of 
your clinical note in the clinical file. 
 
9.3.1.2 Follow up of adverse events 
The IP will provide the attention and guidance of the EA that the participant presents until the end 
of the same, according to what is referred to the following section. 
9.3.1.3 Procedures for a serious adverse event. 
The process of attention of the adverse event considers the following stages: 
 
Figure 3. Attention to the adverse event. 
A. During the development and conduct of the present clinical research, undesirable damaging 
events or adverse reactions, of medical implication, which do not necessarily have a causal 
relationship with the investigational product or investigational medication, may occur in the 
participant patient. These harmful phenomena can occur during the use of investigational 
drugs, unintentionally, at doses authorized for use in humans; by a local, national or 
international regulatory entity, whether for prophylaxis, diagnosis, treatment or for the 
modification of some physiological process. Nevertheless, it can be suspected that the 
investigational product or the investigational drug or the placebo cause some unwanted 
clinical manifestation. Adverse events, adverse reactions or suspected adverse reactions to 
one or several medications can occur during the systematic evaluation of the participants 
(on the days when the clinical review is scheduled, according to the schedule of activities) 
or suddenly, as such way that,  
B. The investigator must be the first person to whom the patient reports that they have 
developed or presented a harmful clinical phenomenon during their participation in this 
research protocol. 
C. According to your clinical judgment; on the basis of the pertinent physical examination, 
interrogation, etc., as well as the analysis of the information available in the medical 
literature and that referred to in the investigator's manual, information to prescribe or 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 46 of 63 
 
technical data sheet of the comparator drug, the principal investigator determines the 
relevant attention of the event / harmful reaction; either. 
D. in the research site or in the hospital with the greatest resolving power (1st, 2nd or 3rd level 
of medical attention). In such a way that, in case the patient is sent by the Investigator to a 
hospital, he / she attends by means of a reference system, it can be with an identification 
card that the patient belongs to the present investigation and there is an official number or 
folio, which pertains to the emergency care agreement with the health institution with the 
greatest resolving power, or a medical reference note issued by the principal investigator, 
so that appropriate care is given to the participating patient. It should be noted that the 
Study Sponsor, Sophia Laboratories, S.A. C.V., will pay the expenses for the medical care of 
the participating patient, only if the adverse event, adverse reaction or suspected adverse 
reaction to medication is associated or found in relation to the investigational product or 
investigational drug. 
E. Taking the clinical information collected, either during the care provided at the research site 
or provided by the treating physician (s) in the hospital, the principal investigator records 
the adverse event, suspected reaction adverse or adverse reaction to medication in your 
clinical note of the clinical record, indicating the seriousness, intensity (mild, moderate or 
severe), relationship with the product or drug under investigation, as well as: 
F. The migration of the relevant data to the case report format and to its respective adverse 
event section; noting the pertinent information, already referred to in section 9.3.1.1., this 
in virtue of the fact that in cases of serious adverse events, which must be notified in less 
than 24 hours after the moment in which the principal investigator has knowledge of the 
same, the clinical monitor of the study is informed, so that in turn he / she informs the 
Scientific Committee and the Pharmacovigilance Department of the sponsor and later he / 
she informs the Research Ethics Committee. Regarding non-serious adverse events, these 
will be recorded and adequately addressed and the corresponding regulatory entity will be 
informed about the safety profile of the product under investigation or investigational 
medication in the final report of the clinical trial. 
 
The record of the outcome of the adverse event, suspicion of adverse reaction or adverse reaction 
to medication depends substantially on the follow-up that the principal investigator makes to the 
participant, since most of the harmful phenomena are expected, consult section of the safety profile 
in number 5.3 and in the researcher's manual, they are ophthalmic in nature, nevertheless there 
may be systemic alterations. Therefore, in the opinion of the researcher, the withdrawal of the 
participant or his / her permanence will be considered, according to the stipulations of section 6.2.2 
Exclusion criteria of the present research protocol. 
 
9.3.1.4 Causality evaluation. 
The assessment of the causality, the methodology used to estimate the probability of attributing to 
a drug, investigational drug or investigational product the adverse reaction, the suspicion of the 
same or the observed adverse event, considers probabilistic categories, according to the evidence 
available and the quality of information, based on national pharmacovigilance regulations. [33] As 
a tool to facilitate the probabilistic categorization of causality, the principal investigator can use the 
algorithm of Karch and Lasagna modified by Naranjo referred to by Aramendi I, 2011 in which 
different items are qualified which allow assigning a value to the relationship cause-effect between 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 47 of 63 
 
the administration of the drug and the adverse reaction. [36] See Table 7. Algorithm of Karch and 
Lasagna modified by Naranjo. 
Algorithm of Karch and Lasagna modified by Naranjo. 
No. 
Reagent 
Score 
Yes 
No 
1. 
There are previous conclusive reports about the adverse drug reaction, adverse 
event or suspected adverse drug reaction 
+1 
0 
2. 
The adverse event appeared when the suspected drug was administered 
+2 
-1 
3. 
Adverse reaction to medication, adverse event or suspected adverse drug 
reaction improved upon discontinuation or administration of a specific 
antagonist 
+1 
0 
4. 
Adverse reaction to medication / adverse event / suspected adverse drug 
reaction reappeared when administering the drug / investigational product / 
investigational medication 
+2 
-1 
5. 
There are alternative causes that may cause this reaction 
-1 
+2 
6. 
Adverse reaction / adverse event / suspected adverse drug reaction occurred 
after placebo administration 
-1 
+1 
7. 
The drug was determined in blood or other liquids in toxic concentrations 
+1 
0 
8. 
The intensity of the adverse reaction / adverse event / suspected adverse drug 
reaction was higher with higher doses or lower with lower doses 
+1 
0 
9. 
The patient has had similar reactions with the drug / product under 
investigation or investigational medication, in the past 
+1 
0 
10. 
Adverse reaction / adverse event / suspected adverse reaction to medication 
was confirmed with some objective evidence 
+1 
0 
                                                                                                                               Total score 
summation 
Probabilistic category based on the score obtained 
I 
The causal relationship is checked 
≥,9  
II 
It is likely that ADR is due to the drug or product under investigation 
5 a 8 
III 
It is possible that the RAM is due to the drug or product under investigation 
1 a 4 
IV 
The causal relationship is doubtful 
0 
The reagents that the algorithm of Karch and Lasagna modified by Naranjo where each one receives a defined score are shown and 
the final summation allows to estimate the probabilistic category of the cause-effect relationship between the administration of the 
drug / product in research / investigational medicine and the adverse reaction, adverse event or suspected adverse reaction. Consider 
that if the information is not available, a score equal to zero is recorded. 
Table 7. Algorithm of Karch and Lasagna modified by Naranjo. 
In such a way that the degree of certainty to establish the investigational product or investigational 
medication (as appropriate) as the causal agent of the harmful phenomenon that befalls the 
participating patient, can be directly indicated by the principal investigator based on his or her 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 48 of 63 
 
clinical experience or well through the voluntary application of the tool mentioned previously. 
Nevertheless, it is important that the investigator take into account the following arguments in favor 
of the causal relationship:  
 
3. a) Force of association: refers to the number of cases in relation to those exposed. 
4. b) The consistency of the data: that is, the presence of a common characteristic or pattern. 
5. c) The exposure-effect pattern: which determines the relationship with the site of onset, 
time, dose and reversibility after suppression. 
6. d) The biological plausibility: which refers to the possible pharmacological or 
physiopathological mechanisms involved in the development or presentation of the adverse 
event. 
7. e) Experimental findings: for example the appearance of anomalous metabolites or high 
levels of drug or the product of its biotransformation. 
8. f) Analogy: experience acquired with other related drugs, adverse reactions frequently 
produced by the same family of pharmacological agents. 
9. g) Nature and characteristics of the data: objectivity, accuracy and validity of the relevant 
documentation. [37]. 
9.3.2 Responsibilities of the sponsor. 
The sponsor will be responsible, and will cover the expenses derived from the medical attention to 
adverse events related to the product under investigation. 
9.4 Audit 
To guarantee compliance with the PCBs and with all applicable regulatory requirements, Sophia 
Laboratories, S.A. of C.V, the COFEPRIS and / or the CEI could carry out a compliance audit to the 
research center.  
9.4.1 Pre-study audit 
The research centers included in the study will be subject to a feasibility visit prior to the selection 
of the center, where it will be verified that they meet the minimum requirements indicated by the 
sponsor.  
9.4.2 Audit / Inspection during the conduction of the study 
They may take place at any time before, during or after the conclusion of the study. If an audit or 
inspection is performed, the investigator and the institution should agree to allow the auditor / 
inspector direct access to all relevant documents, and will allocate their time and that of their staff 
to the auditor / inspector to discuss the findings and any relevant problems. 
 
10. Ethical considerations 
10.1 Approval of the committees 
 
The present study will be conducted in accordance with the standards of the "Declaration of 
Helsinki, World Medical Association 2013". "Nuremberg Code; Trial of Nuremberg by the 
International Court of Nuremberg, 1947. " "Belmont Report, National Commission for the Protection 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 49 of 63 
 
of Subjects of Biomedical and Behavioral Research, 1979". It will be conducted in accordance with 
the scientific and technical requirements necessary for the registration of medicines for human use 
according to the "Guide to Good Clinical Practices of the International Conference on 
Harmonization" (The International Council for Harmonization, ICH). "International Ethical Guidelines 
for Biomedical Research in Human Beings of the Council for International Organizations of Medical 
Sciences" (Council for International Organizations of Medical Sciences, CIOMS, 2002). "International 
Ethical Guidelines for Epidemiological Studies of the Council for International Organizations of 
Medical Sciences" (Council for International Organizations of Medical Sciences, CIOMS, 2008).  
The Research Ethics Committee and the Research Committee will evaluate the protocol before 
conducting the study and will issue their approval or possible modifications to carry it out. These 
Committees must be notified of any significant changes to the protocol. In addition to the above, 
the current regulations issued by the Ministry of Health will also be complied with. General Health 
Law, NOM 012 Official Mexican Standard NOM-012-SSA3-2012, Which establishes the criteria for 
the execution of research projects for human health. The study is considered as an investigation 
with a risk greater than the minimum according to the Regulation of the General Health Law on 
Health Research, Title Two, Chapter I, Article 17, Category III, published in the Official Gazette on 6 
January 1987. 
Principal investigators, study coordinators or personnel authorized by the sponsor will be evaluated 
by the Research Ethics Committees, Research Committees, and when applicable, the Biosecurity 
Committee; the essential documentation of the research project: research protocol, informed 
consent letter, researcher's manual, subject's diary, as well as those requested, in addition, 
according to local, national or international requirements applicable by regulatory entities.  
The study will not start in the research site if you do not have the confidentiality agreements and 
economic proposal of each of the principal investigators, duly signed and without having previously 
obtained the favorable opinion and / or the approval of the Committees of Ethics in Research, 
Research Committees, and when applicable by the Biosecurity Committee, corresponding. 
The study will not begin without having met the relevant local, national or international regulatory 
requirements and without having the corresponding health authorization. 
10.2 Amendments to the protocol 
The amendment procedure will be relevant when there is a need to make any change to a document 
that is part of the research project or protocol, derived from variations to the methodological 
structure, substitution of the principal investigator or when identifying risks in the research subjects. 
The documents susceptible of amendment will be: protocol, letter of informed consent, researcher's 
manual, documents for the patient, scales of measurement and schedule of activities. 
Any amendment must be approved by the sponsor and / or the principal investigator, the amended 
document (s), once reviewed and approved by the Research Ethics Committee and the Research 
Committee or when applicable, by the Committee of Inquiry. Biosafety, (entities that issued the 
initial favorable opinion for the conduct of the investigation) will be sent (s) for authorization by the 
relevant regulatory entity. 
Amendments that substantially modify the protocol or confer an additional or different risk to the 
research subjects, must be approved by the corresponding committees. It is the investigator's 
responsibility to take action in situations that require immediate action to avoid unnecessary harm 
to study participants. 
The principal investigator has the responsibility to inform the Research Ethics Committee of any 
amendment to the protocol that could eventually affect the rights, safety or welfare of the research 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 50 of 63 
 
participants. Likewise, he must know any situation or new knowledge that shows a greater risk for 
the participants, the termination or premature suspension of the study, the reasons and the results 
obtained up to that moment. You must also inform about the conclusion of the study, when 
completing the research protocol. 
The list of amendments, and in the necessary cases, the relation of the issuance of errata, will be 
referred to in the final report of the investigation. 
10.3 Consent  
10.3.1 Obtaining 
Informed consent must be obtained before the subject undergoes any procedure indicated in the 
protocol. 
The written consent documents will incorporate the elements of informed consent described in the 
Declaration of Helsinki and the ICH Guide to Good Clinical Practices and will be in compliance with 
all applicable laws and regulations. 
The IP will provide the potential participant with all the information regarding the characteristics of 
the study, its potential benefits, risks, objectives and procedures thereof. 
This information will be with a language understandable to the subject, it will be explained to the 
subject that has the right to interrupt their participation in the study at any stage, without affecting 
the relationship with the researcher and / or their future assistance. The informed consent will be 
put to the consideration of the possible participant; This must have enough time to analyze each 
and every one of the aspects mentioned above and if there is any doubt this will be clarified by the 
person in charge of obtaining the informed consent. 
Once the participant agrees to participate in the study, he / she must sign and date the informed 
consent letter in the presence of two witnesses who have or are not related to the subject of study, 
who will participate during the informed consent process and will sign endorse that the process was 
carried out prior to any study procedure, that the information of the study was clearly explained 
and doubts were clarified in case of existing. 
If a subject is illiterate, the acceptance will be with their fingerprint, and in the event that the subject 
is not able to grant an informed written consent, a representative of the "legally authorized" subject 
can provide such consent. The subject in accordance with applicable laws and regulations. 
 
The IP must also sign and date this consent. 
The informed consent must be signed in duplicate by all involved, and two witnesses, one copy will 
be filed in the file of the subject and the other will be delivered to the participant. The PI must 
document in the patient's medical history, the date on which he signed the informed consent. 
10.3.2 Special considerations. 
The auxiliary studies that will be carried out during the conduction of the study (laboratory tests) do 
not pose an additional risk that should be considered apart from the procedures listed in the 
informed consent. 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 51 of 63 
 
10.3.3 Modification to informed consent. 
Any change to "informed consent" constitutes an amendment to this document and must be 
submitted for approval to the Research Ethics Committees, and if applicable before the Competent 
Authorities. 
The amendment will include a copy of the new version in the language or languages of the country. 
Such amendments may be implemented only after obtaining the written approval of the Research 
Ethics Committee and the Regulatory Entity (as applicable), with the exception of an amendment 
that is required to eliminate an immediate danger to the subjects of the study. 
Each subject affected by the amendment must complete, date and sign two originals of the new 
version. The subject will be given a signed original of the amendment and the researcher will keep 
the second original. 
10.4 Confidentiality 
All documents and information provided to the researcher by the sponsor are strictly confidential. 
The researcher expressly agrees that the data on their professional and clinical experience, provided 
to the sponsor on paper and stored in electronic format, are only for use related to their activities 
with the sponsor of clinical studies, in accordance with Good Clinical Practices. The researcher 
accepts that he / she and the members of his team will use the information only within the 
framework of this study, to carry out the protocol. This agreement is mandatory as long as the 
confidential information has not been disclosed to the public by the sponsor. The protocol of the 
clinical study provided to the researcher may be used by him and by his colleagues to obtain the 
informed consent of the subjects for the study. The clinical trial protocol, like any information taken 
from it, should not be disclosed to other parties without the written authorization of the sponsor.  
The researcher will not reveal any information without the prior written consent of Sophia 
Laboratories, S.A. of C.V, except to the representatives of the Competent Authorities, and only by 
request of the same. In the latter case, the researcher undertakes to inform Sophia Laboratories, 
S.A. of C.V before revealing the information to these authorities. 
The researcher will fill out and maintain a record of the subjects' selection, as well as the 
identification and enrollment list of each of the subjects participating in the study. The researcher 
agrees to give on-site access to the auditor and / or the representatives of the Competent 
Authorities. The information will be treated in compliance with professional secrecy.  
10.5 Deviations 
A deviation is any alteration in the procedures and activities described in the research protocol 
approved by the committees and regulatory authorities. They may be the product of modifications 
or omissions, and may compromise the safety of the participants or the quality of the data 
generated. 
Major deviation / violation: is one that impacts one or more of the following aspects: 
- 
- Subject security 
- 
- Alteration of the risk-benefit balance 
- 
- Commit the integrity of the study data 
- 
- It affects the voluntariness of the subject in the participation of the study. 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 52 of 63 
 
The list of examples cited below serves the purpose of guidance, but does not cover all possible 
cases, so it is not limiting: 
I. 
In relation to informed consent: 1) that informed consent has been taken by an 
unauthorized person to do so, 2) that the subject under investigation signs a version of 
informed consent not approved by the committees and regulatory entity, 3) that perform a 
study procedure prior to signing informed consent. 
II. 
Regarding the inclusion / exclusion criteria: 1) enroll subjects who do not meet all the 
inclusion criteria and / or meet any exclusion criteria, 2) enroll defined subjects as part of 
the so-called vulnerable population: children, pregnant women, prisoners, without prior 
approval for such group; 3) Enroll patients before the start or after the end of the study. 
III. 
In relation to the medication of the study: error in the delivery or dosage of the same. 
IV. 
In relation to concomitant medication: use of prohibited medication. 
V. 
In relation to the study procedures: that those that, in the opinion of the principal 
investigator, compromise the safety of the research subject are not carried out. 
VI. 
In relation to the reporting of serious adverse events: those that are reported outside the 
time stipulated by the committees.  
Minor deviation: is that which does not impact on the safety of the subject, does not alter the risk-
benefit balance, does not compromise the integrity of the study data or does not affect the subject's 
willingness to participate in the study. 
The list of examples cited below serves the purpose of guidance, but does not cover all possible 
cases, so it is not limiting: 
I. 
Oblivion in the taking of the study medication. 
II. 
Lack of return of study medication by the subject. 
III. 
Visits of the research subject carried out outside the window. 
10.5.1 Management of deviations 
 
All deviations must be reported by the IP to the sponsor and the corresponding committees. 
At your discretion, and depending on the severity of the deviation, the sponsor and the 
corresponding committees may: 
- 
Request more information. 
- 
Citing the principal investigator and / or the members of his team. 
- 
- Temporarily suspend the researcher for present and / or future investigations until the 
situation is resolved and / or considers the explanations given by the person (s) responsible 
for the deviation satisfactory. 
- 
- Conduct an audit for cause. 
10.6 Declaration of interests 
The PI is committed to making a declaration of financial interests, as well as a conflict of interests 
prior to the start of the study. 
10.7 Access to information 
The final database of the study will be owned by Sophia Laboratories, S.A. of C.V and your access 
will be restricted. The IP will not have access to it, unless it has prior written authorization from the 
sponsor. 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 53 of 63 
 
10.8 Auxiliary care and after the end of the study 
Once the study is completed and the adverse events are closed according to section 9.3 Adverse 
events, the sponsor will not extend care on the research subject. 
10.9 Biosecurity aspects 
WITHOUT BIOSECURITY IMPLICATIONS 
The present protocol, with the title: "Phase I clinical study, to evaluate the safety and tolerability of 
the ophthalmic solution PRO-174 versus Sophixín Ofteno®, prepared by Sophia Laboratories, S.A. of 
C.V on the ocular surface of ophthalmologically and clinically healthy subjects ", and number: 
SOPH174-0816 / I DOES NOT HAVE BIOSECURITY IMPLICATIONS, since infectious-contagious 
biological material will NOT be used; pathogenic strains of bacteria or parasites; viruses of any kind; 
radioactive material of any kind; genetically modified animals and / or cells and / or plants; toxic, 
dangerous or explosive substances; any other material that endangers the health or physical 
integrity of the personnel of the research center or the subjects of investigation or affects the 
environment. In addition, it is stated that cell, tissue or organ transplant procedures or cell therapy 
procedures will not be carried out in this project, nor will laboratory, farm or wildlife animals be 
used. 
10.10  Final report and publication of results 
10.10.1 Final report 
Once the statistical analysis is finished, a final report will be drafted with the results obtained, in 
charge of the Scientific Committee of the Department of Clinical Operations of Sophia Laboratories, 
S.A. of C.V Said report will be prepared following the recommendations of the E3 Step 4 Guide of 
the ICH. 
10.10.2 Communication of results 
Regardless of the results in the study, Laboratorios Sophia, S.A. de C.V., is committed to 
communicate the final report of the study to the principal investigators and to the corresponding 
regulatory entities of the countries with participating research centers. Maintaining at all times the 
rights on the publication and dissemination of the information contained.  
10.10.3 Publication of the results 
Sophia Laboratories, S.A. C.V., acting as the sponsor of the study, assumes full responsibility for its 
function and retains exclusive ownership rights over the results of the study, which may be used in 
the manner it deems appropriate. 
The PI undertakes not to publish or communicate data collected only in a center or in part of the 
centers before the publication of the full results of the study, unless prior written authorization is 
obtained from Sophia Laboratories, S.A. of C.V 
Any publication and / or communication project related to the study and / or the results obtained 
during the study or after the completion of the study will be presented to participating medical 
researchers at least 30 days in the case of a publication and 15 days in the case of a summary, before 
the scheduled date for the communication and / or presentation of a publication. The medical 
researcher or doctors will comment on the project within 15 days in the case of a publication and 7 
days in the case of a summary, from the date on which the project is received. 
Nevertheless, in case the sponsor is in the process of submitting a patent application on the results 
of the study, the sponsor may delay its publication or communication of the results of the study 
until the date of registration. 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 54 of 63 
 
11. Bibliographic references 
Bibliografía 
 
[1]  D. Yolton y S. Haesaert, «Anti-infective Drugs,» de Clinical Ocular Pharmacology, St Louis, MO, 
Butterworth Heinemann Elsevier, 2008, pp. 175-220. 
[2]  K. Yeung y J. Sheppard, «Medscape. Drugs & Diseases. Bacterial Conjunctivitis.,» Medscape, 
10 08 2016. [En línea]. Available: http://emedicine.medscape.com/article/1191730-overview. 
[Último acceso: 29 08 2016]. 
[3]  S. Scoper, «Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro 
and in-vivo efficacy,» Adv Ther, vol. 25, nº 10, pp. 979-994, 2008.  
[4]  T. Shields y P. Sloane, «A comparison of eye problems in primary care and ophthalmology 
practices,» Fam Med, vol. 23, nº 7, pp. 544-546, 1991.  
[5]  B. Udeh, J. Schneider y R. Ohsfeldt, «Cost effectiveness of a point-of-care test for adenoviral 
conjunctivitis,» Am J Med Sci, vol. 336, nº 3, pp. 254-264, 2008.  
[6]  H. van-Weert, E. Tellegen y G. Ter-Riet, «A new diagnostic index for bacterial conjunctivitis in 
primary care. A re-derivation study.,» Eur J Gen Pract, vol. 20, nº 3, pp. 202-208, 2014.  
[7]  IMSS, «Diagnóstico y tratamiento de conjuntivitis en el primer nivel de atención,» Evidencias 
y recomendaciones. Catálogo Maestro de Guías de Práctica Clínica: IMSS-035-08, Ciudad de 
México, México., 2015. 
[8]  A. Smith y C. Waycaster, «Estimate of the direct and indirect annual cost of bacterial 
conjunctivitis in the United States,» BMC Ophthalmol, vol. 25, pp. 9-13, 2009.  
[9]  A. Sheikh, B. Hurwitz, C. van Schayck, S. McLean y U. Nurmatov, «Antibiotics versus placebo 
for acute bacterial conjunctivitis. Cochrane Database of Systematic Reviews. Ed. 9,» John 
Wiley & Sons, Ltd, 2012. 
[10] Santen Pharmaceutical Co., Ltd., Cravit ophthalmic solution: prescribing information., Osaka, 
Japón., 2005.  
[11] Vistakon Pharmaceutical LLC, Quixin (levofloxacin ophthalmic solution) 0.5%: prescribing 
information (online), Available: https://www.drugs.com/pro/quixin.html.  
[12] P. Rose, «Management strategies for acute infective conjunctivitis in primary care: a 
systematic review.,» Expert Opin Pharmacother, vol. 8, nº 12, pp. 1903-1921, 2007.  
[13] K. Drlica, «Mechanism of fluoroquinolone action,» Curr Opin Microbiol, vol. 2, nº 5, pp. 504-
508, 1999.  
[14] G. Keating, «Levofloxacin 0.5% Ophthalmic Solution,» Drugs, vol. 69, nº 9, pp. 1267-1286, 
2009.  

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 55 of 63 
 
[15] V. Anderson y C. Perry, «Levofloxacin: a review of its use as a high dose, short-course 
treatment for bacterial infection.,» Drugs, vol. 68, nº 4, pp. 535-565, 2008.  
[16] M. Raizman, J. Rubin, A. Graves y E. al, «Tear concentrations of levofloxacin following topical 
administration of a single dose of 0.5% levofloxacin ophthalmic solution in healthy volunters,» 
Clin Ther, vol. 24, nº 9, pp. 1439-1450, 2002.  
[17] R. Wagner, M. Abelson, A. Shapiro y e. al, «Evaluation of moxifloxacin, ciprofloxacin, 
gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue,» Arch 
Ophthalmol, vol. 123, nº 9, pp. 1282-3*letter, 2005.  
[18] D. Healy, E. Holland, M. Nordlund y e. al, «Concentrations of levofloxacin, ofloxacin, and 
ciprofloxacin in human corneal stroma tissue and aqueous humor after topical 
administration,» Cornea, vol. 23, nº 3, pp. 255-263, 2004.  
[19] H. Sakamoto, M. Sakamoto, Y. Hata y e. al, «Aqueous and vitreous penetration of levofloxacin 
after topical and/or oral adminisration,» Eur J Ophthalmol, vol. 17, nº 3, pp. 372-376, 2007.  
[20] D. Hwang, D. Schanzlin, M. Rotberg y e. al, «A phase III, placebo controlled clinical trial of 0.5% 
levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis,» Br J 
Ophthalmol, vol. 87, nº 8, pp. 1004-1009, 2003.  
[21] S. Kitano, Y. Miyanaga, S. Ohno y e. al, «Clinical evaluation of TN-362a in bacterial 
conjunctivitis: a multicenter, double-masked, 0.5% levofloxacin ophthalmic solution control 
study,» Atarashii Ganka, vol. 23 Supl, pp. 95-110, 2006.  
[22] I. Schwab, M. Friedlaender, J. McCulley, S. Lichtenstein, C. Moran y L. B. C. A. C. S. Group, «A 
phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin 
ophthalmic solution for the treatment of bacterial conjunctivitis.,» Ophthalmology, vol. 110, 
nº 3, pp. 457-465, 2003.  
[23] Y. Shimomura, Y. Ohashi, K. Matsumoto y e. al, «Phase III comparative study of moxifloxacin 
ophthalmic solution in bacterial conjunctivitis,» Atarashi Ganka, vol. 24, nº 10, pp. 1381-1394, 
2007.  
[24] J. Szaflik, J. Szaflik, A. Kaminska y e. al, «Clinical and microbiological efficacy of levofloxacin 
administered three times a day for the treatment of bacterial conjunctivitis,» Eur J 
Ophthalmol, vol. 19, nº 1, pp. 1-9, 2009.  
[25] Y. Kanda, T. Kayama, S. Okamoto y e. al, «Post-marketing surveillance of levofloxacin 0.5% 
ophthalmic solution for external ocular infections,» Drugs, vol. 12, nº 4, pp. 177-185, 2012.  
[26] J. Kanski, Oftalmología Clínica, Barcelona: Elsevier, 2009.  
[27] M. Michel, W. Sickenberg y H. Pult, «The effectiveness of questionnaires in the determination 
of contact lens induced dry eye,» Ophthal Physiol Opt, vol. 29, pp. 479-486, 2009.  
[28] N. Efron, «Grading scales for contact lens complications,» Ophtalmic Physiol Opt, vol. 18, pp. 
182-186, 1998.  
 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 56 of 63 
 
[29] European Group of Graves Orbitopathy, «Eugogo,» ETA, [En línea]. Available: 
http://www.eugogo.eu/_downloads/clincial_evaluation/CHEMOSIS-GO.pdf. [Último acceso: 
11 Abril 2016]. 
[30] International Dry Eye WorkShop 2007, «Methodologies to diagnose and monitor dy eye 
disease,» Ocul Surf, vol. 5, nº 2, pp. 108-152, 2007.  
[31] P. Foster, R. Buhrmann, H. Quigley y J. GJ, «The definition and classification of glaucoma in 
prevalence surveys,» Br J Ophthalmol, vol. 86, nº 2, pp. 238-242, 2002.  
[32] A. Brooks, R. West y W. Gillies, «The risks of precipitating acute angle-closure glaucoma with 
the clinical use of mydriatic agents,» Me J Aust, vol. 145, nº 1, pp. 34-36, 1986.  
[33] Secretaría de Salud México, «NORMA Oficial Mexicana NOM-220-SSA1-2012, Instalación y 
operación de la farmacovigilancia.,» Diario Oficial, 2013.  
[34] International Conference on Harmanisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use, «Clinical Safety Data Management: Definitions and Standards 
for Expedited Reporting E2A,» ICH Harmonised Tripartite Guideline, vol. 4 version, 1994.  
[35] International Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use, «General Considerations for Clinical Trials,» ICH Topic E8, 
1998.  
[36] I. Aramendi, L. Ardao, M. Oyarzun, M. Pérez, I. Olmos y M. Frontini, «Problemas relacionados 
con medicamentos en pacientes hospitalizados en el Hospital Vilardebó,» Rev Psiquiatr Urug, 
vol. 75, nº 2, pp. 123-133, 2011.  
[37] R. Meyboom, A. Egberts, I. Edwards, Y. Hekster, F. Koning y Gribnau, «Principles of signal 
detection in pharmacovigilance.,» Drug Safety, vol. 16, pp. 355-365, 1997.  
[38] BMJ 
, 
«BMJ 
Best Practice 
Acute 
conjunctivitis,» 
BMJ, 
[En 
línea]. 
Available: 
http://bestpractice.bmj.com/best-practice/monograph/68.html. [Último acceso: 28 08 2016]. 
 
 
 
 
 
 
 
 
 
 
 
 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 57 of 63 
 
 
 
 
 
 
 
 
 
 
 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 59 of 63 
 
12. Signature page 
Medical manager of the study: 
Dr. Leopoldo Martín Baiza Durán 
Director of the study: 
Dr. Aldo Arturo Oregon Miranda 
Protocol authors: 
Dr. Oscar Olvera Montaño 
Dr. Arieh Roldán Mercado Sesma 
Internal reviewer of the protocol: 
QFB. Virginia Manuela Villa Felix 
External reviewer of the protocol: 
  Dr. Elia Pamela Chávez Cedillo 
Principal investigator of the study: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 60 of 63 
 
 Page left intentionally blank

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 61 of 63 
 
13. Annexes 
13.1 Eye comfort index 
 
SOPH174-0816-I
/
/
Iniciales del sujeto:
No. de sujeto: 174-______-_______
Indicaciones:
Este cuestionario fue diseñado para calificar el confort de sus ojos.
Para cada pregunta circule su respuesta
Ejemplo:
En la semana pasada, ¿qué tan seguido sus ojos estuvieron rojos?
No existen respuestas correctas o incorrectas. No tome demasiado tiempo en cada pregunta.
1
En la semana pasada, ¿qué tan seguido sus ojos se sintieron secos?
Cuando sus ojos se sentían secos , por lo general, ¿qué tan intensa era la sensación?
2
En la semana pasada, ¿qué tan seguido sus ojos se sintieron arenosos ?
Cuando sus ojos se sentían arenosos , por lo general, ¿qué tan intensa era la sensación?
3
En la semana pasada, ¿qué tan seguido sus ojos sintieron punzadas ?
Cuando sus ojos sentían punzadas , por lo general, ¿qué tan intensa era la sensación?
4
En la semana pasada, ¿qué tan seguido sus ojos se sintieron cansados ?
Cuando sus ojos se sentían cansados , por lo general, ¿qué tan intensa era la sensación?
Hoja 1 de 2
No lo he sentido
Severo
0
1
2
3
4
5
6
No lo he sentido
Nunca
Siempre
0
1
2
3
4
5
6
Severo
0
1
2
3
4
5
6
No lo he sentido
Nunca
Siempre
0
1
2
3
4
5
6
Severo
0
1
2
3
4
5
6
No lo he sentido
Nunca
Siempre
0
1
2
3
4
5
6
6
Siempre
Severo
0
1
2
3
4
5
0
1
2
3
4
5
6
5
6
Nunca
Siempre
Índice de Confort Ocular
Nunca
No. de estudio
Fecha: 
0
1
2
3
4
Ficha de identificación

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 62 of 63 
 
 
5
En la semana pasada, ¿qué tan seguido sus ojos se sintieron adoloridos ?
Cuando sus ojos se sentían adoloridos , por lo general, ¿qué tan intensa era la sensación?
6
En la semana pasada, ¿qué tan seguido sus ojos sintieron comezón ?
Cuando sus ojos sentían comezón , por lo general, ¿qué tan intensa era la sensación?
Nunca
Siempre
0
1
2
3
4
5
6
Severo
0
1
2
3
4
5
6
No lo he sentido
No lo he sentido
Índice de confort ocular
Hoja 2 de 2
Índice de confort ocular, traducido del Ocular Comfort Index disponible en: http://iovs.arvohournals.org
Severo
0
1
2
3
4
5
6
Nunca
Siempre
0
1
2
3
4
5
6

PRO-174 
 
Clinical study protocol: SOPH174-0816/I  
CONFIDENTIAL                                                               Version: 1.1 
 
Page 63 of 63 
 
13.2 Efron scale for conjunctival hyperemia 
 
13.3 Oxford Scale 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Normal 0 
Very slight 1 
mild 2 
Moderate 3 
Severe 4 
Equal or less than panel A 
Equal to or less than panel B, greater 
than A 
Equal to or less than panel C, greater 
than B 
Equal to or less than panel D, greater 
than C 
Equal to or less than panel E greater 
than D 
Greater than panel E 
Grade 
Criterion